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ABSTRACT 
The enchanting process of brain development entails a fragile and finite time window, 
throughout which biochemical imbalances and external insults can potentially affect 
developing neuronal circuits. Within the numerous exquisitely orchestrated events taking 
place in the foetal brain, axonal pathfinding is of paramount importance. If aberrant, axonal 
outgrowth can lead to errors in synaptogenesis and impaired connectivity, with potential 
long-lasting behavioural phenotypes. Despite the prominent role of endocannabinoids (eCBs) 
in axonal guidance, the molecular determinants of eCB-mediated axonal regulation remain 
largely unexplored.  
Aiming to interrogate the eCB machinery in less explored subcortical territories, study I 
investigates the role of the eCB system and its underlying components in foetal cholinergic 
projection neurons. Prenatal manipulation of cannabinoid receptor 1 (CB1R) permanently 
reshaped septo-hippocampal cholinergic projections. Nerve growth factor (NGF) was 
identified as an upstream molecule capable of regulating 2-arachydonoylglycerol (2-AG) via 
monoacylglycerol lipase (MAGL) degradation. The compartmentalization of each eCB 
machinery component along extending neurites is therefore crucial. However, axonal 
pathfinding takes place within the extracellular matrix, migrating glia and developing 
oligodendrocytes, generating a convoluted scenario where each growth cone interacts with 
multiple guidance proteins. Cannabinoid receptor 2 (CB2R)-expressing oligodendrocytes are 
introduced in study II as an additional player able to drive aberrant callosal axons spread upon 
supra-physiological 2-AG levels. Excess 2-AG engaged CB2R-mediated premature proliferation 
of oligodendrocyte end-feet. The interaction between the oligodendrocyte-derived 
chemorepellant molecule Slit2 and its receptor roundabout 1 (Robo1) on corticofugal axonal 
ends induced errant CB1R-expressing corticofugal axon pathfinding. In addition to being an 
endogenous receptor of eCBs, CB1R is also a target for the principal psychoactive compound 
of cannabis, ∆9-tetrahydrocannabinol (THC). In study III we undertook an unbiased 
proteomics screening of the embryonic cortical plate following maternal THC exposure. 
Superior Cervical Ganglion 10 (SCG10), a microtubule-binding protein present in extending 
growth cones, was identified as a direct molecular target of THC. Thus, microtubule dynamics 
represent a novel target of prenatal THC exposure, whose impairment promotes axonal 
defects and long-lasting synaptic connectivity impairment. Cholecystokinin (Cck)-containing 
interneurons, due to their high expression of CB1Rs and early appearance in the developing 
cortex, are likely targets of in utero eCB imbalances. Taking advantage of the recent 
CckBAC/DsRed mouse line in study IV we achieved a systematic anatomical and physiological 
characterization of Cck-CB1R-expressing cells from embryonic day (E)10.5 to adulthood. In 
sum, multiple upstream and downstream molecular components of the eCBs system were 
assessed over the course of this thesis investigation, within both physiological brain 
development and upon maternal cannabis exposure. 
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1 INTRODUCTION 
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1.1 MILESTONES OF BRAIN DEVELOPMENT IN MICE AND MEN 
Neuroscience, like other biological sciences, grounds its knowledge on experimental animal 
models. Thanks to an increasing economical commitment and to the exponential technical 
advancements made over the last 30 years, preclinical studies have led to a massive 
expansion of our understanding of the mechanisms and illnesses of the brain. Data derived 
from primates and humans remain the minority due to an ensemble of ethical, economical 
and technical reasons. This scenario will likely persist into the near future despite the recent 
development of in vitro human technologies, such as cerebral organoids [1, 2] and human 
neuronal cultures derived either by induced pluripotent stem cells (IPSC) or embryonic stem 
cells (ESC) [3]. Thus, the vast majority of our knowledge of brain function has relied heavily on 
model organisms, predominantly rodents due to the numerous genetic tools available. 
Despite the observation that the human brain exhibits architectural principles and 
neurodevelopmental processes that are often conserved across all mammals, interspecies 
differences [4] [5, 6] ultimately yield species-specific behaviours.  
Humans have a prolonged development, with longer gestational time, as well as expanded 
childhood [7] and adolescence maturation [8]. Consequently, the human brain develops at a 
slower pace compared to mice and others primates, generating a wider time window 
vulnerable to genetic and environmental factors that contribute to shape cognitive 
capabilities and eventual neural circuit disorders [9] (Figure 1). Moreover, the developing 
central nervous system (CNS) possesses species-specific anatomical features, especially in the 
neocortex, such as the characteristic subplate region [10] and unique properties of its 
proliferative zone, neuronal stem cells and progenitors [11, 12].  
The evolving nature of the brain has granted humans the privilege of higher cognitive 
function. However, this evolution has required adjustment and refinement of numerous 
neurodevelopmental features and their timing, resulting in a novel vulnerability to particular 
disorders, such as intellectual disabilities and psychiatric disorders. Limitations of 
experimental animal models in modelling neurodevelopmental disorders are therefore not 
surprising [13]. Thus, being aware of species-specific neurodevelopmental patterns is central 
when planning experiments and interpreting ensuing results.  
The first section of this introduction will describe developmental milestones in the human 
CNS and report, when significant, differences that exist in mice. Developmental mechanisms 
will focus primarily on studies from the neocortex, mainly because of the higher number of 
comparative studies available. 
1.1.1 Gross structures development 
From gestation through adolescence, human brain development is a two decades-long 
process, spreading from embryonic progenitors’ assembly until cell death and synaptic 
pruning in late adolescence [14]. Within this time a predicted final number of 86.1 billion 
neurons (adult male, [15]) find their correct locations and establish appropriate connections, 
generating an estimated 164 trillion synapses in the adult human neocortex [16].  
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Figure 1. Evolution-driven increase in brain complexity. The evolving nature of the brain generated 
higher complexity of cognitive functions that characterizes humans. The required prolonged 
gestation contributed to generate critical windows along brain development and human-specific 
neurodevelopmental disorders. Gestational periods, brain weight and brain total cells are compared 
within mouse, macaque monkey and human. Data adapted from [15]. 
 
Human gestation typically lasts 38 weeks. The embryonic period begins at conception and 
extends through post conception week 8 (8 pcw), from which the foetal period begin (9 pcw 
till the end of gestation) [17]. By the end of the 3 pcw the embryo differentiates from a two 
layered structure into a three layered structure, a process known as gastrulation [18]. 
Neuroectodermal stem cells emerge during this phase and are capable of differentiating into 
any cell type present in the brain. The neuronal tube is formed during 3 pcw, when two 
ridges develop along the two sides of the neural plate, where neural progenitors lie [19]. 
During the next few days the ridges rise and close generating a cylindrical cavity, which 
eventually develops into the ventricular system of the brain [18]. By the end of the embryonic 
period five primary embryonic vesicles are formed along the rostral-caudal axis: the most 
anterior telencephalon and diencephalon, both derived from the prosencephalon,  
precursors of the forebrain; the middle mesencephalon, future midbrain; and the caudal 
metencephalon and myelencephalon, precursors of the hindbrain [17, 18]. Within the foetal 
period the human brain transforms from a smooth lissencephalic structure to a complex 
combination of gyri and sulci [18]. The longitudinal fissure starts caudally as early as 8 pcw, 
and it is completed in its rostral part at 22 pcw, separating the two cerebral hemispheres 
[20].  
1.1.2 Neurogenesis and maturation of excitatory cells 
Human neurogenesis starts as early as 4 pcw in the spinal cord and brain stem [18], and 
proceeds at location-specific rates during embryogenesis and foetal development with minor 
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postnatal contributions at defined locations. The majority of excitatory neurons are produced 
before 27 pcw [21] within the inner wall of the neural tube cavity, called the ventricular zone 
(VZ), and the adjacent subventricular zone (SVZ). Epithelial progenitors in the VZ differentiate 
into a population of stem cells, called radial glia (RG) progenitors [22]. The RG progenitor pool 
exponentially proliferates via symmetric cell division between 25 and 42 post conception 
days (pcd), resulting in a dramatic enlargement of the SVZ and VZ during early gestation. RG 
progenitors can divide symmetrically generating two daughter RG cells, or asymmetrically, 
yielding an intermediate progenitor cell (IPC) and a differentiated neuron [23]. Neurogenesis 
switches from a symmetrical to an asymmetrical mode around 50 pcd, when postmitotic 
neurons leave the proliferative zone and start to radially migrate in the developing neocortex 
in a subtype characteristic manner [18]. As discussed above, the timeframe of brain 
development in humans differs from other species, largely due to its complexity. This is best 
appreciated in the cortical neurogenesis timeframe, which is estimated to last ~143 days in 
humans (from 48 to 191 pcd), compared to 67 days in the macaque (from 45 to 112 pcd) and 
11 days in mouse (from 11 to 21 pcd) [24] (see http://www.translatingtime.net/ for further 
neurodevelopment time differences across species). Despite the time differences, cortical 
glutamatergic pyramidal neurons are generated from RG progenitors of the VZ and migrate 
radially in the cortical plate (CP) in both humans and rodents [25].  
Before glutamatergic cortical neurogenesis commences, a peculiar neuronal population 
develops, including reelin-expressing Cajal-Retzius cells and predecessor cells, and starts to 
migrate tangentially from outside the neocortex where they settle above the VZ, forming the 
outer marginal zone (MZ) [22]. MZ-resident early born cells have a central role to ensure 
correct cortical development, regulating laminar organization and early synaptic contacts of 
principal cells [26]. Below the MZ, the subplate zone (SP) gains tremendous importance 
during pregnancy. The SP prenatally expands to become the largest compartment of the 
developing cortex [10]. Recent studies highlighted the exceptional nature of the SP region 
(see below), revealing its transient nature, the heterogeneity of the population involved, an 
interesting set of human-specific features and the involvement of subplate neurons in 
developmental brain disorders [10]. During late foetal development, while SP neurons are 
reduced [10], CP neurons migrate to their final position in a precise inside-out manner [27], 
where they start to differentiate complex dendritic arbours and form local synaptic 
connections. Pyramidal cells develop basal and apical dendrites in the CP around 15 pcw [28], 
followed by the first synapse establishment around 18 pcw [29] and only later by dendritic 
spine development between 24 and 27 pcw [28]. Although starting during midgestation, 
synaptogenesis continues postnatally until the second year of life and peaks between 3rd and 
15th month of life. Synaptogenesis is followed by a long period of synaptic reorganization, 
where extrinsic and intrinsic factors drive synaptic pruning [30]. Major synaptic elimination 
and dendritic contact reinforcement continues through childhood and adolescence [31], with 
both processes essential for maturation of cognitive functions.  
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1.1.3 The long migratory journey of interneurons   
In contrast to the short radial journey of excitatory cells, human γ-aminobutyric acid (GABA)-
expressing inhibitory neurons destined to populate the cortex are generated within a 
transient germinal zone in the ventral telencephalon and undergo a remarkable tangential 
migration prior to radial migration [11, 12]. Ventral ganglionic eminences are anatomically 
divided into medial, caudal, and lateral (MGE, LGE and CGE), and are conserved across 
multiple species including rodents [32].  From these structures, a multitude of interneuron 
subtypes are generated, whose identity and heterogeneity largely overlaps between higher 
primates and rodents [10, 33]. 
Enormous progress has been achieved through investigations using animal models 
elucidating the spatial and temporal dynamics of interneuron development [32, 34-40]. 
Recent studies on humans and nonhuman primates revealed novel interspecies differences, 
both at genetic [5, 41, 42] and developmental levels [10, 12]. For example, even though the 
precise magnitude and molecular mechanisms are still under debate, dorsal telencephalic 
VZ/SVZ progenitors are proposed as an additional source of GABAergic cortical interneurons 
in primates, an evolutionary novelty contributing to the elaboration of higher cognitive 
functions [12].  
1.1.4 Glia and brain development 
Once confined to supportive and protective functions, glial cells have more recently assumed 
a central role in brain development. Human oligodendrocytes and astrocytes are derived 
from the RG progenitor pool at midgestation [23], with a peak around birth and sustained 
development through the postnatal period [43]. Gliogenesis is therefore extremely 
protracted in humans compared to mice [44], suggesting glia possible involvement in the 
evolution of neocortical cognitive functions. 
Cortical astrocytes proliferate after a first step of direct differentiation from RG cells [23, 45]. 
Human astrocytes proliferate and differentiate mostly postnatally, during the 3rd postnatal 
year [46]. A minor morphologically mature prenatal population was identified in the 
neocortex as early as 15 pcw [45]. Interestingly, the timing of differentiation of astroglial cells 
overlaps with synapse development in the neocortex, suggesting a potential primary role in 
synaptogenesis [47, 48], dendritic spine formation [49] and synaptic pruning [50].  
Along the same line, the majority of oligodendrocytes are generated through the first 3 years 
of life, with a protracted region-specific postnatal maturation process up to the third decade 
of life [43]. Oligodendrocyte maturation in non-human primates, studied in chimpanzees, is 
instead mostly complete by adolescence [44]. During development and preceding 
myelination, neuronal interactions with oligodendrocyte precursors appear to have a 
significant functional role in regulating axon guidance and synaptic plasticity [51]. Moreover, 
oligodendrocyte precursors receive synaptic inputs from interneurons, generating a transient 
synaptic network [52] required for oligodendrocyte maturation. Once successfully 
differentiated, oligodendrocytes generate myelin sheaths around most axons, which are 
necessary for fast axonal conduction. Axonal myelin maturation inhibits cellular dynamism, 
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possibly leading to the end of the highly plastic synaptic rearrangement that characterizes 
adolescence. Interestingly, myelination and myelin dysfunctions seem to be highly specific for 
certain interneuron subclasses [53]. Inappropriate myelination of parvalbumin expressing 
interneurons (PV) was indeed proposed as a pathological locus responsible of PV 
interneurons functional impairment in schizophrenia [53].  
1.1.5 The subplate: cells and development  
Being one of the most diverse structures across different species, the subplate zone of the 
human brain is characterized by a transient dramatic expansion during pregnancy [54, 55]. 
The SP region plays critical roles in circuit assembly, being the intermediate target of long-
range projection neurons and location of the first synaptic contact between migrating cortical 
neurons and ingrowing afferent fibres [55]. Populated by a heterogeneous population of 3.6 
billion cells at its expansion peak around 31 pcw [56], the subplate zone is enriched in 
extracellular matrix, glial cells, migratory glutamatergic neurons, GABAergic neurons and 
cortical/subcortical axonal terminals [55, 57]. At 12-15 pcw the human subplate originates 
from the deeper cortical plate and becomes the dominant structure of the embryonic cortex 
[55]. The expansion in volume is characteristic of the “subplate stage” from 15 to 35 pcw, due 
to the massive ingrowth of axons invading the cortex, including thalamocortical afferents 
[58], forebrain cholinergic afferents [59], as well as contralateral and ipsilateral cortical 
projections [60]. From 35 pcw the human SP enters the final “dissolution stage” when its 
total volume shrinks due to a rapid decrease in the number of inhabiting cells, of extracellular 
space and axonal bundles [55]. Six months after birth the subplate is no longer visible in 
human tissue. In contrast, in rodents the subplate is not clearly identifiable by histological 
criteria and does not expand in volume during development [61]. The meaning of such 
diversity is at present unclear. 
The origin of SP cells is heterogeneous, including both radially migrating excitatory cells 
originating from the SVZ together with ganglionic eminence-derived inhibitory neurons. The 
rostro-medial telencephalic wall (RMTW) generates an additional early born population of SP 
neurons [62]. RMTW-derived cells migrate dorsally to reach the cortex, spread through the 
subplate and secondarily colonize the nascent cortical plate by tangential migration, where 
they mature as Cajal-Retzius cells and deep-layers interneurons [62]. Even though only a few 
studies are available, interesting data have come from SP birth-dating experiments, both in 
primates and in mice [63]. Only early born neurons enter the SP and settle as part of the 
resident population, while cells born later do not take up residence in the SP, but rather 
migrate through [63]. Gene expression and ontology analyses have revealed early maturity as 
a characteristic hallmark of subplate neurons that are functionally enriched for axonal 
growth, cell adhesion, exocytosis as well as synaptic plasticity-related genes [64]. Moreover, 
recent transcriptome experiments in mice and humans have highlighted an expected human-
specific pool of gene transcripts of the developing subplate, including genes involved in the 
production of extracellular matrix and proteoglycans, not present in the adjacent zones [65]. 
SP cells have in fact a distinctive early axonal protrusion, mature morphology and membrane 
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properties, compared to the cells populating the rest of the cortical plate, consistent with the 
earlier establishment of synaptic inputs to SP cells [66].  
In addition to their diversity in origin, birthdate, and neurotransmitters, SP neurons are also 
morphologically heterogeneous during development [67] with fusiform, multipolar, 
polymorphic and inverted pyramidal shapes. At birth fusiform and polymorphic types are 
equally presents both in monkeys and humans [67]. In the adult, the morphology and 
function of the remaining cells is however less clear. With described species-specific 
variations, SP cells are the first cortical cells to send subcortical projections [68]. Both SP 
interneurons [69, 70] and excitatory cells [68] appear to form long range projections, the 
latter being responsible for ipsilateral cortical module maturation [61]. 
The cellular complexity of the SP zone mirrors multiple functional roles during development, 
highlighted by timed subplate ablation and misplacement experiments [71, 72]. Subplate 
neurons play critical roles early in development through thalamocortical axonal pathfinding, 
laminar positioning and synapse maturation, as well as in the establishment of sensory areas 
and oscillatory activity (for a comprehensive review on SP functions during development see 
[61]). Taken together the evidence indicates that the SP serves as a transient corridor for 
migrating excitatory and GABAergic neurons enriched in surface molecules, extracellular 
matrix and growth factors, where migratory switches and synaptic contacts take place. 
Subplate involvement in nervous system disorders such as  epilepsy [73], schizophrenia [74] 
and autism [75] is therefore not surprising and worthy of  further attention. 
1.1.6 Critical windows along brain development 
The emergence of human higher cognition, with its unique capabilities of abstract thinking 
and language, is the product of 300 million years of evolution of the mammalian brain [76]. 
The resultant complexity of the human CNS relies on a plethora of novel human-specific 
features, particularly evident in the neocortex. These include the introduction of new 
cytoarchitectonic areas, an increased complexity of the cortical columns, new genes and 
unique cell types [77]. The prolonged developmental time typical of the human brain 
described above is therefore an evolutionary necessity to achieve this higher complexity [14]. 
The trade-off for this two decades long maturation time [6] is however the opportunity for 
environmental and genetic risk factors to perturb or undermine the assembly of the 
physiological network. It is therefore not surprising that diseases in which human-specific 
behaviours are disturbed, such as intellectual disabilities, autism spectrum disorders and 
psychiatric disorders, happen to have a developmental origin [78].  
The importance of intrauterine homeostasis has indeed been highlighted by numerous 
studies, causally linking neurological phenotypes to maternal infections, hypoxia, obesity and 
diet composition [79]. The idea of a perinatal non-genetic “maternal programming” consists 
therefore of maternal presentation of environmental or metabolic stimuli, specifically 
harmful because of their coincidence with critical windows during brain development [79]. 
The “double-hit” hypothesis was proposed for several neuropsychiatric disorders, where 
early perinatal environmental insults may lead to neuronal circuit vulnerability, while a 
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second “hit” during a later period, such as adolescence, may induce the onset of the disease 
[80, 81] (Figure 2). Hence maternal illicit drug use, inflammation and viral exposure during 
pregnancy have all been associated with cognitive/learning deficits and an increased risk of 
schizophrenia in offspring [82]. Moreover, delivery complications at birth [83] as well as 
stressor events during early development [84] positively correlate with psychiatric disorders. 
Furthermore longitudinal studies showed that behavioural phenotypes including intellectual 
disabilities incidence increases in offspring of obese mothers [85]. Revealing the signalling 
mechanisms connecting maternal inputs and offspring neurodevelopment, therefore, gains 
major significance. 
Several milestones of brain development have been associated with GABAergic cells [78]. 
Although interneurons constitute only a minority of the total cortical neuron population 
(estimated to be ~15-20% in rodents [86]), they play crucial roles in network assembly, 
possibly explaining the involvement of GABAergic cells in a number of cognitive disorders 
[78]. In humans, as in rodents, GABA-mediated depolarization [87] provides the main source 
of synchronization [88] during embryonic and early postnatal time periods, which is required 
for correct activity-driven circuit development [89]. At birth, oxytocin drives a temporary 
switch of GABAergic signalling to inhibitory [90], by a reduction in intracellular chloride, which 
likely serves to protect against hypoxic stress during delivery. In rodents, the final maturation 
from excitation to inhibition for GABAergic transmission does not occur until the end of the 
first postnatal week [87], when the ultimate upregulation of chloride transporter expression 
in principal cells takes place. This postnatal switch of GABAergic signalling to providing 
inhibitory drive induces the maturation of interneuron-mediated fine-tuned responses that 
characterize human brain. This phenomena is known as desynchronization of the 
spontaneous network activity, and happens coincident  with the initial  sensory experiences, 
such as vision [91].  
While less significant in adulthood, lack of correct stimuli exposure within critical windows of 
development have long-lasting effects [92]. Genetic and pharmacological experiments have 
highlighted GABAergic neurons as the principal gatekeepers of developmental critical 
windows [93]. Of the heterogeneous populations of inhibitory cells, PV-expressing fast-
spiking interneurons are the major source of inhibition onto principal cells [94]. Moreover, PV 
interneuron maturation induces synchronous oscillatory activity in the neocortex, which is 
required for the establishment of functional connectivity between the hippocampus and the 
prefrontal cortex [95]. Interestingly, recent studies on schizophrenia pathophysiology have 
highlighted the central role of PV interneurons in disease onset [95, 96]. In general, multiple 
GABA receptors and overall inhibitory synapses are altered in schizophrenic patients [97] and, 
interestingly, in asymptomatic high-risk individuals [78].  
To conclude, GABAergic interneurons play major roles in determining many of the critical 
windows of brain development, highlighting an interesting timed overlap between 
interneuron-mediated developmental events and neuropsychiatric disorder inception [98]. In 
addition to schizophrenia, interneurons are involved in the aetiology of a growing list of 
neuropsychiatric and developmental neural circuit disorders, including autism [99], epilepsy 
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[100], Rett's syndrome [101], fragile X syndrome [102], neurofibromatosis type I [103], 
Angelman's syndrome [104] and bipolar disorder [105]. Understanding how and when 
specific interneuron subtypes participate in each of these conditions will provide informed 
strategies for early therapies in high-risk individuals [98, 106], with a goal to not only treat 
symptoms but to prevent disease emergence. 
 
 
Figure 2. The “double-hit” hypothesis. Timeline of major neurodevelopmental events in human and mouse. 
Circles contain predicted timing of specific processes [24]. The age of onset of most prevalent 
neurodevelopmental disorders are represented as distribution curves [107].  The “first hit” consists of early 
perinatal insults, including maternal infections, diet imbalances and drugs abuse. Notice how the “first hit” 
coincides with key events during neurodevelopment (such as neurogenesis, migration, projections development 
and with the beginning of synaptogenesis and gliogenesis) therefore possibly leading to circuit vulnerabilities. A 
“second hit” later in time, possibly represented by drug abuse or adverse life events and stress during 
adolescence, may induce disease onset. The “second hit” overlaps with critical events for network maturation 
(such as synaptic pruning, myelination, and gliogenesis).                             
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1.2 CELLULAR AND MOLECULAR LANDSCAPES OF AXONAL PATHFINDING 
All developing neurons are required to sense the surrounding environment in order to target 
their correct postsynaptic partners. The sensory tips of each axonal projection, the growth 
cones, are highly motile and dynamic structures able to perceive the environment and 
address axons to their targets through the correct migratory path. Santiago Ramon y Cajal, 
who first described the growth cone structure in 1892, became aware of its nature using only 
silver-impregnation and his devoted observation skills:  
"From the functional point of view the growth cone may be 
regarded as a sort of club or battering ram, endowed with 
exquisite chemical sensitivity, with rapid amoeboid movements, 
and with certain impulsive force, thanks to which it is able to 
proceed forward and overcome obstacles met in its way, forcing 
cellular interstices until it arrives at its destination." [108] 
Of all his observations, Cajal was certainly intrigued by the “intelligent force” driving the 
growth cone and its capability of chemical attraction by substances produced by the target 
structures, a phenomenon later named “chemotropism”: 
“How does the mechanical development of the nerve fibers 
occur, and wherein lies that marvellous power which enables the 
nerve fibers from very distant cells to make contact directly with 
certain other nerve cells or the mesoderm or ectoderm without 
going astray or taking a roundabout course. [...] If a chemotaxic 
sensitivity in the neuroblasts is assumed, then it must be 
supposed that these cells are capable of amoeboid movement 
and are responsive to certain substances secreted by cells of the 
epithelium or mesoderm [109]. The processes of the neuroblasts 
become oriented by chemical stimulation, and move toward the 
secretion products of certain cells.” [110] 
Almost a century later the netrin family was identified in the developing axons of the spinal 
cord [111], representing first described chemoattractant cue and ultimately supporting 
Cajal’s intuitions. Two decades later, the first live imaging of a growth cone [112] revealed its 
dynamic nature,  a key feature responsible of the “intelligent” behaviour observed by Cajal.  
1.2.1 Cytoskeletal dynamics of the growth cone  
Macroscopically the growth cone appears as an enlarged terminal, present at the end of each 
axon and dendrite. The peripheral region (P region) of the growth cone is a flat area 
characterized by membrane protrusions named either lamellipodia, if enlarged and 
supported by a meshwork of branched actin filaments (F-actin), or filopodia when structurally 
maintained by long parallel bundles of actin linear arrays [109] (Figure 3). Extension of the 
lamellipodia and filopodia is a major dynamic event characterizing the peripheral region and 
is crucial for growth cone movement. The backbone of the dynamic tip of each axon, F-actin, 
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is the molecular target for numerous signalling cascades, and is regulated by a wide range of 
proteins involved in actin assembly/disassembly, crosslinking, end capping and monomer 
sequestering [113]. Extensive literature can be found for each of these families, including 
WASp [114], Arp2/3 [115], capping proteins [116, 117], ADF/cofilin [118] and 
thymosin/profilin [119]. Optimal regulation of actin-associated proteins is critical for the high 
active turnover typical of explorative young growth cones and their sequential switch into 
mature neurons, characterized by relatively stable F-actin (for extensive reviews on 
cytoskeleton dynamics see [113, 120, 121]). 
 
 
Figure 3. The growth cone and its cytoskeleton.  The tip of the growth 
cone can be divided in three structural regions, distinct in function and 
cytoskeletal components.  The C region (grey) connects the growth cone 
to the axonal shaft and contains the majority of microtubules (green). 
The T zone (orange) is the intermediate zone that controls growth cone 
motility and contains actomyosin contractile structures known as actin 
arcs (blue).  The outer region, or P zone (yellow) is the motile and sensory 
region of the axon. It is characterised by enlarged lamellipodia supported 
by branched F-actin networks (blue) and filopodia, containing F-actin 
bundles (magenta), F-actin networks (blue) and pioneer microtubules 
(green). Modified from Lowery et al [109].  
 
Central to the outer structure is the body of the growth cone (C region), which is connected 
to the axonal shaft, and supports the movement of growth cone tips and contains 
mitochondria and exocytotic vesicles [109].  Structurally the C region is characterized by 
microtubules, a minority of which extend to an intermediate region between the body and 
the outer zone, known as the transitional zone (T zone), where actomyosin contractile 
structures (actin arcs) control growth cone motility [122]. Microtubules are polar structures 
comprising heterodimers of α and β subunits, each of which consists of 13 protofilaments 
[123]. The polarity of microtubules results in one fast-growing end named the “plus end” 
pointing the P zone and the opposite, slow-growing, “minus end” facing the C region [124]. 
The minus end is often capped and sequestered at the body of the growth cone [125]. At the 
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distal region of the neurite the plus end of individual microtubules extends to reach the actin-
rich peripheral domain. Here a complex and continuous series of growing and shortening 
events take place, a process called dynamic instability [126]. Early pharmacology experiments 
revealed that the dynamic behaviour of microtubules is responsible and necessary to achieve 
axonal extension [126]. Cytoskeleton dynamic instability is therefore a key feature of the 
growth cone, necessary for its ability to quickly remodel upon extracellular signals.  
Dynamic instability is regulated by two principal categories of molecules: microtubule 
stabilizer and destabilizing proteins [127]. Microtubule-associated proteins (MAPs) belong to 
the first category [128]. Strategies adopted to stabilize microtubules include increasing the 
frequency of dimers rescue, binding the microtubule polymer, and bundle formation upon 
microtubule crosslinking [121]. Amongst microtubule destabilizers, the stathmin family has 
been identified as intracellular factors that promote microtubule depolymerisation by likely 
increasing the rate of “catastrophe” events [129-131].  
1.2.1.1 SCG10 controls microtubule dynamics via JNK1 
Amongst stathmins, a family of ubiquitously expressed proteins involved in the physiological 
regulation of microtubule dynamics [132, 133], the neuron specific member SCG10 (also 
named brain-specific stathmin-2) was initially identified as a neuronal marker in the neural 
crest [134]. SCG10 expression is neuron-specific and finely upregulated during development 
[129]. SCG10 is richly localized to outgrowing neurites both in the developing retina [135] and 
in cortical neurons [129], and is strongly downregulated after synapse formation [129]. 
Moreover, in the rat olfactory system SCG10 expression is restricted to immature olfactory 
neurons, and is highly upregulated after injury during olfactory axon regeneration [136]. 
Although the molecular cascade(s) involved is not yet fully understood, early studies suggest 
a principal role for SCG10 in axonal development and regeneration. 
One of the first studies aimed at dissecting the intracellular cascade downstream of stathmin 
pointed out that SCG10 overexpression in vitro inhibits microtubule polymerization in a dose 
dependent manner [137]. The mechanism by which this happens is similar to stathmins’ 
ability to sequester tubulin molecules [138]. SCG10 binds tubulin dimers, generating a ternary 
complex (“T2S”) of one SCG10 molecule and two α/β tubulin dimers [139] (Figure 4). Tubulin 
sequestration lowers the amount of intracellular available soluble tubulin dimers, resulting in 
an overall inhibition of the polymerization of microtubule filaments [140] and an increase in 
catastrophe events. SCG10 also acts at the minus end of microtubules where it mediates 
instability by increasing the shortening rate [141]. 
Cellular levels of SCG10 are regulated by post-translational modifications such as 
phosphorylation [133]. Mass spectrometry revealed four phosphorylation sites on SCG10: 
Ser50, Ser97, Ser62 and Ser73 [142]. SCG10 phosphorylation by c-Jun N-terminal Kinase 1 
(JNK1), the brain specific isoform of 
 the JNK family [143], was described as a neuronal specific pathway in axonal degeneration 
[144] and multipolar stage exit during neuronal migration [145]. JNK1 recruitment 
phosphorylates SCG10 specifically on Ser62 and Ser73, inducing SCG10 inactivity and 
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proteasomal degradation [144]. JNK1 was already introduced as an intracellular component 
involved in extracellular axon guidance [143]. JNK-mediated SCG10 degradation is therefore 
mechanistically appealing as a rapid on-demand cellular mechanism for regulating 
cytoskeleton dynamics in response to extracellular guidance molecules. However, the 
upstream extracellular signals capable of inducing this intracellular pathway remain to be 
explored. 
 
 
Figure 4. SCG10 controls microtubule dynamic instability. (A) Microtubules are cylindrical polar 
structures consisting of tubulin protofilaments. Each tubulin heterodimer consists of α (light green) 
and β subunits (dark green), each tightly bound to its GTP molecule (blue). Stathmin-2/SCG10 (red) 
binds to two tubulin heterodimers, forming a ternary complex. Adapted from Essential cell biology, 
Garland science [146]. (B) SCG10 availability controls microtubule dynamism. SCG10 forms ternary 
complexes with tubulin heterodimers at the plus end of each protofilament, promoting catastrophe 
events and microtubules instability. JNK1 leads to SCG10 degradation via proteasome after inducing 
SCG10 phosphorylation. SCG10 reduced availability results in a more stable microtubule [144]. (C) 
Schematic illustration of SCG10-mediated catastrophe events.  SCG10 binds at the minus end of the 
microtubule, capping the exposed α-tubulin and prevents the incorporation of new dimers, thus 
stabilizing the minus end. At the plus end SCG10 promotes instead catastrophe events by multiple 
mechanisms: inhibiting lateral interactions between protofilaments, inducing curvatures and 
increasing GTPase activity at the uncapped ends, overall destabilizing the tip and mediating 
catastrophe events. In sum, SCG10 contributes to generate microtubule asymmetric catastrophe 
events at the two polar ends. Adapted from Gupta et al [147].  
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1.2.2 Molecular guidance cues orchestrate axonal outgrowth  
The intrinsic ability of growth cones to sense their surroundings implies an evolutionarily 
conserved preference of specific axons for certain migratory pathways. Migrating cells are 
indeed able to sense a wide range of guidance cues, including localized molecular cues [148], 
chemical [149] and electrical gradients [150] as well as mechanical signals [151]. While the 
latter have only started to be recently explored, from Cajal onwards, increasing efforts have 
been invested in identifying and characterizing the molecular cues involved in the extension 
of the axonal tip. Because of the large number of existing guidance cues, their expression 
must be finely regulated in order to reproduce the correct pattern of axonal outgrowth [152]. 
The expression patterns of guidance cues segregate between subcellular structures and cell 
types [152]. Although we focus here on the guidance of primary axonal growth cones, the 
extending neurite often branches forming secondary growth cones [153]. Collateral sprouts 
are initiated and directed by the same guidance cues as the primary growth cone [153]. 
Accepting the limit of categorization in specific contexts, individual molecular guidance cues 
fall into three main classes: adhesive cues, trophic signals and chemotropic guidance cues. 
Adhesive cues include extracellular matrix components (ECMs) and cell adhesion molecules 
(CAMs), both generally recognized by specific receptors on the growth cone [154] (Figure 5). 
ECM subtype distributions, including those for laminin, collagen, fibronectin and a variety of 
proteoglycans, define a substrate as permissive or non-permissive [154]. ECM receptors are 
typically part of the Integrin family [155]. Notably neurons are able to express their 
preference on specific ECMs depending on the type of Integrin receptor expressed [156]. A 
combinatorial variety of CAMs are expressed not only in neurons but also in glial cells [157]. 
Immunoglobulin (Ig) and calcium-dependent cadherin represent the two major families of 
CAMs [158]. Members these superfamilies mediate axonal guidance either via heterophilic 
interaction or through homophilic adhesion, acting as ligand or receptor in opposing cells 
[159]. More than 50 neuronal CAMs are encoded in mammals, each with specific interactive 
extracellular domains and intracellular signalling cascades [158]. 
Trophic signals are by definition molecules that promote cell survival.  However additional 
roles in axonal outgrowth have been highlighted for numerous trophic signals, including 
neurotrophins [160], insulin-like growth factor (IGF) [161] and hepatocyte growth factor 
(HGF) [162]. Mammalian neurotrophins are a heterogeneous family of small molecules that 
include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 
(NT3) and neurotrophin 4 (NT4). Neurotrophins activate a multi-receptor signalling network 
that triggers a variety of complex intracellular cascades, driving a plethora of cellular events, 
including cell survival, cell death, promotion and inhibition of neurite outgrowth [160] (for an 
extensive review on the intracellular cascades engaged by neurotrophins see [160]). Two 
principal receptor types bind mature neurotrophins: 1) the low affinity p75NTR, a member of 
the tumor necrosis factor (TNF) superfamily; and 2) the high affinity tropomyosin-related 
kinase receptor (Trk) family [163, 164]. Each neurotrophin family member selectively binds 
Trk receptors: NGF binds to TrkA; BDNF and NT4 bind to TrkB; and NT3 binds to TrkC; all 
neurotrophins bind to p75NTR [163, 164]. Exceptions to this rule, together with regulatory 
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intermediates within each intracellular signalling cascade, highlight neurotrophins as one of 
the most finely regulated guidance mechanisms.  
Chemotropic guidance cues are often secreted molecules that establish attractant or 
repellent gradients, able to impart directionality from a distance on the growing axon. 
Alternatively, guidance cues can be transmembrane or surface bound molecules, and 
influence growth cones only locally [154]. Of the first type, netrins are a small family of 
diffusible molecules with an interesting bifunctional role capable of repelling some axons 
while attracting others [165]. Slit family, secreted but exclusively chemorepellant, bind 
Robo1/2 receptors and control the guidance of the major axonal tracts and interneuron 
migration in the developing brain [166]. The large family of Semaphorins includes both 
secreted and transmembrane chemorepellent proteins [167]. Netrins, Semaphorins and Slits, 
each act through their own receptor families to achieve specific guidance outcomes by 
regulating the activity of Rho GTPases, which in turn modulate cytoskeleton dynamics [148]. 
 
 
Figure 5. Molecular guidance cues drive axonal outgrowth.   Axonal outgrowth takes place within 
numerous chemoattractive (+) and chemorepulsive cues (-) that generate migratory permissive roads 
(green background) and surrounding repulsive guard rails (red background). Chemoattractive cues 
induce filopodia protrusion by F-actin bundle polymerization and exploratory microtubule recruitment 
at the tip of the P zone (yellow). When the growth cone faces repulsive cues lamellipodia structures 
prevail on the growth cone and microtubules are restricted to the C zone (grey). Repulsive cues 
generated by cells at critical positions (red circles) generate repulsive corridors able to restrict 
permissive territories. Chermorepulsive cues can be transmembrane or secreted and impart 
directionality on certain neurons due to specific receptor expression patterns (red). Along the 
migratory path, axon fasciculation and de-fasciculation events are orchestrated by short-range 
adhesive cues and their receptors (purple). Intermediate guidepost cells (cyan circles), such as glia or 
subplate cells, contribute to growth cone guidance towards final targets (blue circles). Both target 
neurons and intermediate guidepost cells attract migratory neurons generating a gradient of long-
range positive cues sensed by growth cone tips using specific receptors (blue).   
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1.2.2.1 NGF regulates cholinergic projection development in the basal forebrain 
The first neurotrophin to be isolated was NGF, in 1951, by the Italian scientist Rita Levi-
Montalcini [168], recognized for her scientific contribution with the Nobel Prize in 1986. The 
identification of NGF changed the perception of cellular communication confirming that cells 
can target distant organs and communicate by secreted factors.  
NGF is a glycoprotein of 118 amino acids, synthesized as pro-NGF and cleaved either 
intracellularly or after secretion into mature NGF [169]. Once intracellularly synthesized the 
N-terminal sequence of NGF mediates translocation to the endoplasmic reticulum and 
packaging into vesicles before secretion [169]. While the first understood function of 
neurotrophins was cell survival, it soon became apparent that NGF promotes axonal growth 
driving F-actin polymerization in the growth cones and during filopodia formation of sensory 
neurons [169]. NGF is indeed synthesized from target tissues and once secreted interacts 
with its receptors at axonal ends [170]. Even if no data were available at the time, Rita Levi-
Montalcini foresaw NGF chemotactic effects in neurodevelopment. Her words at the Nobel 
Price lecture in 1986 are a testament to her scientific instincts and enthusiasm: 
“The most obvious among the foreseeable approaches is the 
search for other NGF target cells, using the ever more 
sophisticated in vivo and in vitro techniques which became 
available in these last decades. It was this multimodal approach, 
which in recent years led to the discovery of NGF target cells in 
the CNS of lower and higher vertebrates and in cell lineages 
playing a role in the immune system. This list is likely to increase, 
as the search extends to other neuronal and non-neuronal cell 
populations. Furthermore, one should take into account the fact 
that some of these populations are receptive to NGF mainly 
during developmental stages in prenatal life. […] These should 
provide valuable information on some of the still unexplored, 
submerged areas of the NGF iceberg, dealing with the processes 
of the NGF gene transcription or translation” [171]. 
The chemotactic effects of NGF were indeed first described by the Levi-Montalcini laboratory 
in neonatal rats when they observed that an in vivo administration of NGF recruited massive 
growth of fibres towards the NGF source [170]. Subsequent efforts directed at understanding 
the molecular mechanisms mediating NGF actions on axonal growth cones, revealed TrkA 
receptors as the principal players involved in sensing NGF [172]. Once activated, TrkA 
receptors exhibit intrinsic tyrosine kinase activity promoting receptor autophosphorylation 
and subsequent activation of multiple intracellular signalling cascades [172] (Figure 6). Early 
studies on PC12 cells [173] revealed that neurite outgrowth is regulated via TrkA through 
three main enzymes, protein kinase C (PKC), phosphatidylinositol-3 kinase (PI3K) and 
phospholipase C gamma (PLC-γ), all acting downstream on actin [174]. Furthermore, these 
studies showed that neurite elongation and actin redistribution in NGF exposed PC12 cells 
are mediated by decreased phosphorylation of ADF/cofilin [175]. 
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Figure 6. Nerve growth factor (NGF) intracellular signalling. NGF mediates neuronal growth and cell 
survival via the high affinity receptor TrkA and the low affinity receptor p75. TrkA engagement 
causes TrkA receptor dimerization and autophosphorylation, followed by a variety of local 
downstream signalling cascades. TrkA activation-mediated local signalling includes the recruitment 
of PKC pathway via PLCγ, Akt pathway via PI3K, and cytoskeleton reorganization leading to axonal 
outgrowth (for an extensive description of NGF-mediated intracellular cascade see [163]).  
Activated TrkA receptors within axonal terminals are internalized into vesicles and transported to 
the soma. In the soma ERK5 is activated and transported to the nucleus where it regulates gene 
expression. TrkA-mediated gene regulation includes mediators of axonal outgrowth, synapse 
differentiation and cholinergic markers.  NGF induces cell survival via low affinity receptor p75 and 
NF-κB mediated gene regulation, while JNK-mediated cell death may be promoted by receptor p75 
upon limiting amounts of NGF. Modified from https://www.qiagen.com/us/shop/genes-and-
pathways/pathway-details/?pwid=456.   
 
The roles of NGF in axon outgrowth, survival, and repair were extensively studied in long-
range projections of basal forebrain cholinergic neurons targeting the cortex and 
hippocampus. Basal forebrain-hippocampal cholinergic projections have a central role in 
memory and attention processes [176] and are found to be dysfunctional in Alzheimer’s 
disease [177]. Recent studies aiming to improve cholinergic cell survival in neurodegenerative 
diseases have, therefore, focused on neurotrophins, particularly NGF [178]. NGF synthesized 
in the cortex and hippocampus regulates development [179], cell size and dendritic 
arborisation of basal cholinergic neurons [180]. In the hippocampus NGF is produced by 
pyramidal neurons [181], glial cells [182], dentate granule neurons and subpopulations of 
GABAergic interneurons [183]. Though details of regulated NGF production remain to be 
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addressed, evidence indicates that NGF expression in the hippocampus is activity dependent 
[184], and markedly dysregulated under pathological conditions such as seizure, injury [185] 
and inflammation [182]. Once NGF binds to its receptor it has to be internalized and 
retrogradely transported along the axon towards the cytoplasm and the cell nucleus. This was 
initially revealed by retrograde accumulation of 125I-labelled NGF in basal forebrain 
cholinergic cells following hippocampal injections [186]. Moreover, septo-hippocampal lesion 
results in atrophy of the cholinergic cells and over-accumulation of NGF in the hippocampal 
region [186]. These were the original observations that led to the hypothesis of a retrograde 
transport of NGF from the growth cone to the nucleus where gene expression could be 
consequently regulated [187]. The multiple pathways through which NGF transduces 
neurotrophic signals into gene expression are today mostly described, including the above 
cited PI3K, PLC-γ as well as mediators of survival and apoptosis such as Jun Kinase (JNK) and 
Nuclear factor Kappa B (NF-κB) [160]. Phenotypic knockout of NGF revealed that basal 
forebrain and hippocampal cholinergic neurons survival are particularly sensitive to NGF 
[188]. Additionally, NGF promotes the cholinergic neuronal phenotype by driving expression 
of cholinergic markers such as choline acetyltransferase (ChAT) [189] and vesicular 
acetylcholine transporter (VAChT) [190] with consequent regulation of acetylcholine 
synthesis and release [191]. Within the cholinergic system endogenous NGF is critical for 
cortical synapse differentiation and maintenance, as demonstrated by studies using anti-NGF 
monoclonal antibodies, TrkA receptor antagonists and TrkA knockout animals [192]. 
However, potential coordination between NGF and other secondary molecular effectors 
highly co-expressed in basal forebrain cholinergic projections, such as endocannabinoids 
[193], remains to be investigated. 
1.2.2.2 Slit/Robo interactions modulate axonal pathfinding of major axonal tracts 
Slit/Robo signalling was one of the first chemotropic guidance cue programs discovered 
[194].  First  identified in Drosophila, where they control midline crossing of commissural 
axons [195], Slit/Robo interactions have central roles in the guidance of thalamocortical 
axons (TCA), cortico-cortical projections through the corpus callosum and corticofugal 
projections [196, 197].  
TCA outgrowth from the diencephalon into the ventral telencephalon is initiated at E12.5 in 
mouse [198]. TCA fibers cross the striatum and enter the cortical plate by E14.5 [198]. Along 
their journey TCAs are guided by numerous guidance cues, such as neuregulins and 
guidepost cells, which promote extension and correct directionality of TCAs [199]. Numerous 
studies have defined a pivotal role for Slit/Robo signalling in TCA targeting [196, 200, 201]. 
Various combinations of Slit1/2 and Robo knockout mice exhibit thalamocortical targeting 
defects during their developmental trajectory [196, 202], and Robo1-/- mice have enlarged 
TCA bundles [203]. Moreover, Robo expression is regulated by Lhx2 and Gbx2 transcription 
factors (TFs) [204] [205] and both Lhx2 and Gbx2 mutant mice display defective TCA targeting 
[204, 205]. 
Slit/Robo signalling is critical for corpus callosum development and both Robo1/2 and Slit2 
mutants present abnormal callosal projections [196]. A recent set of interesting studies 
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proposed that Slit1/3 controls callosal projections indirectly by regulating the glial population 
resident in this region [206], supporting the hypothesis that glial-neuron interactions direct 
axonal guidance. In glial cells, as in neurons, TFs regulate Slit2 expression [207]. Furthermore, 
glial expression of Slit2 is transcriptionally regulated by Gli3, which if absent perturbs corpus 
callosum development and relocates Slit2+ midline glial cells [207]. 
In 20 years of research Slit/Robo signalling has extended well beyond its classical role in 
midline crossing and axonal pathfinding [196], being implicated in the migration of cortical 
neurons [208, 209], spine formation [210], dendrite development [211, 212] and cortical 
progenitor proliferation [213]. Despite numerous extensive studies on axonal tract 
development [194, 196, 197, 206, 214, 215], Slit/Robo signalling cascades and cellular 
functions remain incompletely understood. Moreover, while appealing, the hypothesis of 
axon-glia joint control over axonal outgrowth via Slit/Robo signalling [206, 207] requires 
further investigation. 
1.2.3 Axon-glia interactions in neuronal pathfinding 
Recent literature has moved beyond a model where axonal outgrowth is driven strictly by 
intrinsic developmental programs residing exclusively within the extending neurite. Rather, 
models proposing an interactive multiplayer scenario critically dependent on glia-neuron 
interactions, especially in early stages of development, are gaining popularity [216].  
Glial cells act as guideposts, located at crucial decision points along migratory routes, towards 
which cells are attracted and further directed to their final target structure  [217]. As cited 
above, this role was initially described at the midline for regulation of ipsilateral/contralateral 
projections. In this case, glia provided chemorepellant cues, secreting Slit at the midline [214, 
218]. The timed expression of Robo receptors in ipsilateral and contralateral axons, either 
after or before they crossed the midline, was identified as a key mechanism [219, 220]. 
Once outgrowing axons reach their target area, growth cones receive specific targeting cues 
that stop their migratory behaviour and help them to identify correct postsynaptic partners. 
At this stage neurons, as well as glia cells, can act as intermediate temporary target cells. The 
role of glia as intermediate targets has been described for layer selection of retinal axons in 
Drosophila [221]. In vertebrates, the most described intermediate target cells are Cajal-
Retzius cells [222] and subplate neurons [223] described above. Despite limited information 
about non-neuronal intermediate target cells in vertebrates, glia have been proposed to fulfil 
such a role in the rodent olfactory bulb, where olfactory axons contact glia tufted processes 
during glomerular formation [224]. Intriguingly, glia have been shown to interact with axons 
also at later stages, as shown for axonal pruning of mushroom bodies in Drosophila [225] and 
during synaptic refinement [226]. Taken together, the emerging idea of glia and neurons as 
team players in axonal guidance is an interesting and challenging new concept that needs 
further investigation. 
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1.2.4 Complex decisions along the migratory journey: axonal fasciculation 
The guidance molecules and intracellular signalling cascades described separately in vivo take 
place often simultaneously, requiring well-orchestrated control over complex decision points.  
This is exemplified by guidance to and from the midline as well as by recognition of  
intermediate and final targets [148]. Additional interesting complex decisions regulated by 
guidance molecules are axonal fasciculation and de-fasciculation events. 
All of the above described major axonal tracts, such as the TCA and the corpus callosum, 
require the existence of a former extending axon that pioneers the route followed by 
subsequently migrating cells [154, 227]. Though the preference of outgrowing axons to 
migrate on an existing pioneer axon was described almost 100 years ago [228], the cellular 
and molecular mechanisms underlying this event are far from completely understood. This 
phenomenon is known as axonal fasciculation and once again evidence indicates that axon-
glia interactions are crucial. Though glia generate a repulsive signal at turning points, such as 
in the midline, growing axons seems to favour the migration on immature glia, which are 
typically abundant in proximity to emerging tracts [229].  
Axon-axon homotypic interactions are instead critical to create axonal subpopulations within 
bundles required for proper targeting. Homotypic fasciculation has been recently highlighted 
as a key mechanism for the spatial segregation of olfactory sensory neurons [230]. In order to 
achieve such a complex organization, a plethora of guidance molecules are involved to push 
together and pull apart axons during timed fasciculation and de-fasciculation events [154]. 
One class of guidance molecules important during fasciculation is the CAMs family. Among 
the CAMs, Fasciclin II in insects and NCAMs in vertebrates, are major determinants of correct 
axonal fasciculation [231]. Contemporarily, the environment surrounding migrating axons 
provides either a favourable substrate, facilitating the invasion of axonal growth cones, or 
repulsive cues that promote continued fasciculation [158].   
Slit2 facilitates axon fasciculation via an autocrine/juxtaparacrine mechanism in motor axons, 
which exhibit a tendency towards premature de-fasciculation in Slit2 or Robo1 and Robo2 
knockout mice [215].  In addition to guidance molecules axonal fasciculation is also regulated 
by ion channels [232], calcium activity [233] and endocannabinoids [234, 235]. Moreover, 
very recent studies have shown that axonal outgrowth is further sensitive to mechanical 
properties of the surroundings via the mechanosensitive ion channel piezo1 [151], to optical 
stimuli [236], electrical stimuli [150] and modulated by hybrid innovative approaches [237-
239].  
Solving the riddle of axonal pathfinding therefore requires a broad vision, able to embrace 
100 years of classic molecular neuroscience on cytoskeleton dynamics and combine it to a 
variety of guidance cues, signalling cascades and heterogeneous cell populations. This is not 
merely an exciting scenario, but rather an urgent necessity since an increasing number of 
neurological disorders are related to axonal outgrowth deficits [240, 241]. 
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1.3 ENDOCANNABINOIDS AND BRAIN DEVELOPMENT 
The idea of endogenous cannabinoids as a fundamental neuromodulatory system emerged 
more than 30 years ago. However, the therapeutic properties of Cannabis Sativa (麻) were 
described in the oldest Chinese pharmacopoeia, the Shennong Bencaojing (ca 200 BC), the 
first written gathering of oral traditions dating back to the Chinese sovereign Shennong, who 
was said to live around 2800 BC [242]. Despite being known for almost 5000 years, the 
therapeutic value of cannabis was not evaluated scientifically until the beginning of the 19th 
century by the Irish physician Sir William B. O’Shaughnessy during his work in Calcutta [243]. 
The recognition of endogenous cannabinoids was however delayed until the  psychoactive 
components of cannabis were purified: cannabidiol (CBD), first characterized in 1940 by the 
Nobel laureate Lord Alan Todd in the UK [244] simultaneously with the American colleague 
Roger Adams [245]; and THC, first isolated in 1964 by Raphael Mechoulam and Yechiel Gaoni 
[246]. After THC identification, almost two decades of synthetic chemistry were necessary in 
order to identify the first THC-binding site. In 1990 [247] an “orphan” G-protein coupled 
receptor (GPCR) was identified as first cannabinoid receptor in the CNS, followed 3 years later 
by the cloning of a second peripheral receptor for cannabinoids [248].  The isolation of the 
first endogenous ligand shorty followed in 1992, with the characterization of arachidonoyl 
ethanolamine, or anandamide (AEA) [249]. 
1.3.1 Endocannabinoid signalling machinery 
1.3.1.1 Endogenous cannabinoids 
The endocannabinoid system includes eCBs, cannabinoid receptors and the enzymatic 
machinery responsible for the synthesis and degradation of eCBs. Endogenous cannabinoids 
are a family of small signalling lipids able to bind cannabinoid receptors with functional 
similarities to the main psychoactive component of cannabis, THC. The first eCBs to be 
synthesized and the most studied to date are AEA [249] and 2-AG [250]. The family of 
endogenous cannabimimetic and related lipid mediators potentially contains hundreds of 
bioactive molecules [251], emphasizing how our current knowledge on the endocannabinoid 
system might only be the tip of the iceberg.  
2-AG, on which this chapter focuses, is the most abundant cannabinoid in the mammalian 
brain [252]. Structurally, 2-AG is an ester formed from the essential ω-6 polyunsaturated fatty 
acid arachidonic acid and glycerol [250]. Interestingly, the precursors of eCBs are therefore 
part of the cellular lipid membrane. This is a unique feature of eCBs compared to other classic 
neurotransmitters, which are synthesized ahead of need and stored in synaptic vesicles. eCBs 
instead can be released in the extracellular space on demand, liberated from the lipid 
membrane in only a few enzymatic steps, upon cellular depolarization [253-255] or GPCR 
activation [256]. How endocannabinoids cross cell membranes and move extracellularly 
remains unanswered, though it was recently proposed that active endocannabinoids are 
present in secreted microvesicles [257]. 
eCBs are synthesized downstream from arachidonic acid, which itself is derived from an 
essential fatty acid.  This raises an appealing and still poorly studied consideration: because 
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long-chain polyunsaturated fatty acids (PUFAs) need to be introduced in our body by diet, 
that fluctuation in the composition of our diet could possibly modulate the availability of 
eCBs and related signalling molecules [258]. A further development of this concept could 
produce interesting considerations on ω-6 enriched western diets [259] and possibly explain 
the increasing number of studies that correlate fatty acid diet composition to behavioural 
outcomes [258, 260-263]. 
1.3.1.2 Endocannabinoid receptors 
The functional effects of endo- and phyto-cannabinoids are principally mediated by CB1Rs, 
primarily localized within the CNS, and by CB2Rs, highly expressed in the peripheral systems 
as well as in the CNS in lower concentrations. Peroxisome proliferator activated receptors 
(PPARs) and transient receptor potential channels (TRP), as well as other receptors not 
detailed in this section, were also shown to mediate some actions of eCBs [264]. Both TRP 
channels, particularly TRPV1, and PPAR-α /PPAR-γ receptors are activated by AEA, with major 
effects on gene transcription [265, 266]. 2-AG and AEA have specific and unique affinities 
towards different endocannabinoid receptors. While 2-AG is a high-efficacy agonist of CB1Rs 
and CB2Rs, AEA is a low-efficacy agonist of both receptors. CB1Rs and CB2Rs, both GPCRs, 
once activated primarily couple to Gi and G0 proteins, further activating intracellular cascades 
and inducing several cellular functions (for an extensive review on cannabinoid receptors see 
[267]). Cortex, basal ganglia, hippocampus and cerebellum regions display the highest 
expression of CB1Rs [267], cumulatively considered the most abundant metabotropic 
receptor in the brain [268] . Subcellularly, CB1Rs avoid the active zone, despite enrichment 
within presynaptic terminals [269]. While CB2Rs are mainly involved in peripheral functions, 
they are sparsely expressed in the CNS where they are classically described as being 
restricted to microglia and vascular elements [270]. This traditional view has been challenged 
by emerging strong evidence that shows CB2R mRNA in neuronal cells of the hippocampus 
[271] and in dopamine-expressing neurons in the ventral tegmental area (VTA) [272]. CB2R-
mediated modulation of cell type-specific plasticity was described in the hippocampus [273]. 
Moreover, CB2R upregulation in neurons was observed under pathological conditions [274, 
275].  
1.3.1.3 Endocannabinoids synthesis and degradation  
As cited above, AEA and 2-AG contain arachidonic acid backbone. However while 2- 
AG is synthesized from 2-arachidonoyl-containing phospholipids, most AEA is produced from 
N-arachidonoyl phospatidyl ethanol (NAPE) [276]. The enzymatic machinery involved in their 
metabolic pathways is therefore completely distinct. AEA is synthesized via multiple 
pathways which were shown to be brain region specific or related to certain physiological or 
pathological states [276]. Four main routes of AEA synthesis have been described, the first of 
which was by hydrolysis of NAPE via NAPE-phosholipase D (NAPE-PLD) [277]. Subsequent 
studies confirmed that NAPE-PLD ablation affects AEA levels and causes CB1R redistribution 
[278]. Alternatively, AEA can be synthesized by cleavage of the phosphodiester bond of NAPE 
via NAPE-PLC and sequential dephosphorylation, a pathway mainly characterized in immune 
cells [279]. Finally two additional routes of AEA synthesis are i) dual hydrolysis of NAPE by the 
  23 
α/β domain-containing hydrolase 4 (ABHD4) followed by an extra hydrolysis by 
glicerophosphodiester phosphodiesterase I (GDE-1) [280]; and ii) one hydrolysis step by 
ABHD4 followed by AEA liberation via lyso-NAPE-PLD [281]. Even if mechanistically described, 
the roles of the last three synthesis mechanisms in the CNS remain to be determined. There 
are two major routes of AEA degradation: via fatty acid amide hydrolase (FAAH), the major 
route [282]; and alternatively via AEA oxidation through cyclooxygenase-2 (COX-2) [283].  
Most 2-AG is synthesized by hydrolysis of arachidonoyl-containing phosphatidyl inositol bis-
phosphate via PLCβ, resulting in a diacylglycerol (DAG) that is sequentially hydrolysed by a 
diacylglycerol lipase (DAGL) [284]. This last step can be mediated either by DAGLα, seemingly 
responsible for most of the 2-AG synthesis in the adult CNS, or by DAGLβ that is able to 
cooperate with DAGLα in specific conditions [285]. 2-AG can be hydrolytically degraded 
primarily by MAGL, or alternatively by ABHD6 and by ABHD12, each localized within specific 
subcellular compartments [286]. MAGL is responsible for the majority of 2-AG degradation in 
the brain [286]; it is highly expressed in the CNS and mainly localized at the synaptic terminals 
[287]. In contrast, ABHD6 is expressed in dendrites and dendritic spines of pyramidal cells in 
the cortex [288]. Inhibition of either MAGL [289] or ABHD6 [288] can increase 2-AG signalling 
via CB1Rs. Though the ABHD12 metabolic pathway has been molecularly characterized [290], 
its function in vivo remains to be established. Alternative pathways of 2-AG degradation are 
via COX-2 oxidation [291] or FAAH hydrolysis [292]. Historically, DAGLα and MAGL have been 
considered key enzymes in neuronal regulation of 2-AG, exhibiting synaptic segregation 
within pre- and post-synaptic compartments respectively [287].  
In addition to its role in eCB signalling 2-AG also participates in a wide range of other cellular 
functions such as prostaglandin synthesis [293], which should be considered when 
manipulating 2-AG levels [276]. 
1.3.1.4 New insights from CB1R pharmacology 
Despite major efforts invested in the last 25 years delineating CB1R modes of action, recent 
data reported in this section suggest that further investments might be necessary. Indeed, 
new advances in CB1R pharmacology have revealed several natural and synthetic orthosteric 
agonists, such as CP-55,940, antagonists, including rimonabant, and additional endogenous 
cannabinoids [294]. Therapeutic application of rimonabant and other eCB ligands revealed 
significant side effects in humans [295]. This generated interest to develop novel neutral CB1R 
antagonists, known as CB1R blockers [296]. Complicating matters are additional findings 
demonstrating that eCBs also target non-cannabinoid receptors such as G protein-coupled 
receptor 55 (GPR55) [297], as well as ion channels including vanilloid, serotonergic and 
nicotinic receptors [294]. 
Novel therapeutic approaches for manipulating eCB signalling are focusing on putative 
allosteric binding sites and the development of both positive and negative CB1R allosteric 
modulators which may be safer than full receptor agonists and antagonists [298]. Within this 
category indole derivatives, known as “ORG” compounds [299], and urea derivatives, such as 
PSNCBAM-1 [300], are being tested in animal studies. Natural allosteric modulators of CB1Rs 
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have also been described, including lipoxinA4, the hemopressin, pepcan-12 and 
pregnenolone [301]. Moreover, historically known cannabinoids were recently re-discovered. 
CBD, a cannabis component historically considered a CB1R antagonist, was recently 
reclassified to non-competitive negative allosteric modulator [302]. The increasingly accepted 
therapeutic potential of phytocannabinoid-based medicine demands further characterization 
of the actions of these compounds, including their potential allosteric functions.  
CB1R heteromerization with other proteins and receptors was recently shown to significantly 
affect in vivo eCB function, further complicating the picture. CB1Rs have in fact been shown 
to generate heteromers with adenosine A2A receptors in the striatum [303], with 5-HT2A 
serotonin receptors in memory related brain regions [304] and surprisingly with CB2Rs [305]. 
Interestingly, cell membrane fluidity via lipid composition has been proposed as a critical 
regulator of CB1R signalling in neurodegenerative disorders [306]. Even further complexity is 
introduced by observations that CB1Rs can exist in a ligand-free constitutively active mode, 
which has been shown to tonically regulate GABA release in the hippocampus [307]. 
1.3.2 Endocannabinoid spatial and functional heterogeneity 
1.3.2.1 The dogma: endocannabinoids are retrograde synaptic messengers  
eCBs, particularly 2-AG, are historically categorized as retrograde messengers. This conclusion 
arose from observations describing that postsynaptic activity upregulates eCB production, 
that eCB machinery is synaptically compartmentalized and that CB1R engagement inhibits 
synaptic transmission [268]. eCB-mediated synaptic plasticity includes depolarization-induced 
suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). 
DSI and DSE reflect transient suppression of GABA and glutamate release respectively 
following strong postsynaptic neuron activation and are reproduced in slice electrophysiology 
by a step depolarization or repeated action potential firing lasting a few seconds in 
postsynaptic neurons [308] [309]. eCB-mediated short-term plasticity via DSI and DSE were 
described first in the hippocampus [310, 311] and the cerebellum [309] in 2001, promptly 
followed by numerous attempts to characterize underlying molecular mechanisms [268]. 
Exogenous cannabinoid driven activation of these mechanisms were also assessed by 
numerous studies [312, 313].   
Metabotropic-induced suppression of inhibition (MSI) and metabotropic-induced suppression 
of excitation (MSE), also known as synaptically evoked suppression of inhibition and 
excitation, were later described as ubiquitous forms of short-term plasticity [268]. MSI and 
MSE require by definition the engagement of a variety of Gq/11-linked GPCRs, including but 
not limited to metabotropic glutamate receptor 1/5 (mGluR1/mGluR5), M1/M3 muscarinic 
receptors, CckA, orexin A and α1adrenergic receptors [268]. The subsequent intracellular 
calcium dynamics activate calcium-sensitive PLCβ1 [314], resulting in diacylglycerol 
production and consequent release of 2-AG via DAGL. The newly synthesized 2-AG liberated 
in the postsynaptic cell then binds to and activates presynaptic CB1Rs, which transiently 
suppress transmitter release [268].  
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eCBs can also drive long-lasting inhibition of synaptic transmission, known as eCB-mediated 
long-term depression (LTD). LTD is defined as homosynaptic if induced by eCBs generated 
locally within the stimulated cell, typically using persistent low frequency activation of 
glutamatergic synapses [315]. Heterosynaptic eCB-mediated LTD occurs in neighbouring 
synapses that are not activated during the conditioning stimulation. This form of 
metaplasticity has been described in the hippocampus, where excitatory drive from Schaffer 
collaterals can heterosynaptically decrease GABAergic input to principal cells [316]. Given the 
importance of LTD in sculpting cortical circuit development [317], disruptions in eCB-
mediated LTD following cannabis abuse in adolescence may have severe consequences for 
network maturation and cognitive function. 
Finally, neuronal excitability can be directly reduced by eCBs through slow self-inhibition (SSI) 
[318]. With intense stimulations, SSI induces 2-AG synthesis, somatic CB1R activation with 
consequent recruitment of inwardly rectifying potassium channels [319]. Cell-autonomous 
SSI has been observed in low threshold-spiking cortical interneurons [318] cerebellar basket 
cells [320] and cortical excitatory cells [321].  
1.3.2.2 Foci for action: endocannabinoids at Cck+CB1R+ interneurons 
CB1R expression in the CNS is particularly high in the cortex, hippocampus, basal ganglia, and 
cerebellum. CB1R preferential expression within cortical and hippocampal interneurons was 
established shortly after the development of a reliable CB1R antibody [322] with two 
independent groups showing that CB1R expression localized almost exclusively to Cck-
containing GABAergic interneurons [323, 324]. Electron microscopy highlighted CB1R+ axon 
terminals of Cck-containing basket cells innervating the soma and proximal dendrites of 
pyramidal neurons [324].  These findings firmly established Cck presynaptic elements as a 
major substrate underlying eCB-mediated modulation of hippocampal network function. 
Subsequently, numerous studies aimed to dissect eCB-mediated synaptic modulation 
specifically in Cck interneurons in the hippocampus [325-329], amygdala [330, 331], midbrain 
[332] and hypothalamus [333].  
Chole-cysto-kinin (from Greek, literally “bile-sack-move”) was identified in 1975 as a molecule 
of the gastrointestinal tract important for gastric motility [334]. Subsequently, Cck was 
identified as one of the most abundant neuropeptides in the brain, localizing in a cell-type 
specific manner [335, 336]. Cck is derived from its precursor molecule preprocholecystokinin 
[337], via extensive tissue-specific post-translational processing, typically yielding the 
predominant form of Cck in the brain: an 8-amino acid C-terminal fragment (Cck-8s) [338]. 
Cell-type specific Cck expression has been extensively studied in the hippocampus where 
expression is enriched in subsets of GABAergic cells typically referred to as “Cck 
interneurons” [339]. In the hippocampus, one subset of Cck interneurons provides 
perisomatic input to principal cells, thus regulating pyramidal neuron output and synchrony 
[340]. Because of the shape of their axons, these Cck interneurons fall into the category of 
basket cells, innervating selectively the soma and proximal dendrites of postsynaptic targets 
[340].  
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Another family of basket cells, PV-expressing interneurons, has a dominant role in pacing and 
synchronizing network oscillations [341]. In contrast, Cck basket cells are considered to act as 
“fine tuning” modulatory cells, able to receive and integrate inputs from several subcortical 
regions [341]. Cck protein has also been identified in pyramidal excitatory cells in the 
neocortex and the hippocampus, able to modulate glutamatergic excitatory system, possibly 
facilitating glutamate release (for more details on Cck functions in excitatory neurons see 
[342, 343]). 
While convenient as an interneuron subtype marker, the role of Cck neuropeptide is not yet 
completely understood. Studies on Cck peptide functional roles highlighted two principal 
mechanisms of action:  via PV interneurons and within Cck basket cells themselves [344]. Cck-
8s acute application on hippocampal slices was shown to increase pyramidal cell spontaneous 
postsynaptic inhibitory event (sIPSCs) frequency [345, 346] mediated by a selective robust 
activation of PV-expressing basket cells via Cck2 receptors [345]. When the Cck peptide was 
instead applied during paired recordings between Cck basket cells and postsynaptic 
pyramidal cells, inhibition of unitary IPSCs was observed [345]. The proposed mechanism 
behind this phenomenon involves an indirect functional interaction between Cck peptide and 
eCBs. Specifically, Cck receptor activation in postsynaptic pyramidal cells couples through 
Gq/11-protein signalling to drive 2-AG synthesis and release, which then binds to presynaptic 
CB1Rs within Cck basket interneurons [345]. Once activated, presynaptic CB1Rs suppress 
GABA release by inhibiting N-type calcium channels through Gi-protein coupled signalling 
[324]. Cck peptide application therefore promotes an imbalance in pyramidal cell perisomatic 
inhibition by coincidentally increasing and decreasing output from PV and Cck basket cells 
respectively [327, 347]. However, similar modulation of inhibitory tone by endogenous Cck 
has yet to be demonstrated.  CB1R engagement was shown to inhibit the release of 
numerous peptides including Cck [348]. Using combinatorial pharmacological modulation of 
Cck and CB1Rs by selective antagonists, a recent study suggests that CB1R-Cck peptide 
interactions participate in conditioned fear extinction, anxiety and stress [349].  
Interestingly, Cck+CB1R+ interneurons were identified as an early population in brain 
development originating from the CGE at embryonic day E12.5 [350]. Morozov and 
colleagues highlighted an early commitment to the Cck+CB1R+ phenotype and the following 
three-phasic migratory pathway: from VZ of the ventral telencephalon to the MZ of the 
dorsal neocortex, into the hippocampus. Cck+CB1R+ cells migrate tangentially to the 
hippocampal primordium, where they arrive between E13.5 and E15.5 [350]. Because of their 
early CB1R expression, foetal eCB imbalances could dramatically impair the migration and 
differentiation of these Cck expressing cells, potentially precipitating circuit wide deficits in 
network activity. 
1.3.2.3 Not that simple: heterogeneous distribution of CB1R 
Although CB1Rs are primarily localized presynaptically in Cck basket cells and the majority of 
the literature focuses on CB1R-mediated regulation of neurotransmitter release, recent 
evidence points to additional cellular substrates that can mediate eCB functions. For 
example, somatodendritic CB1Rs were shown to control via self-inhibition specific 
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postsynaptic signalling cascades in the cortex [318, 319] and mediate eCB-induced cognitive 
impairments [321]. Indeed, CB1R expression is no longer considered exclusive to Cck basket 
cells, as these receptors have now been well characterized in glutamatergic [351] and 
serotoninergic neurons [352]. Dopamine [353] and acetylcholine [354] release are also 
regulated by eCBs.  CB1R expression within these varied cell types does not necessarily reflect 
an equal distribution, as evidenced by differential CB1R expression in brain regions and within 
cell types [267, 340]. Such a regulated and heterogeneous distribution likely contributes to 
the variety of functional effects of eCBs [276] and may partially underlie the bimodal effect of 
cannabis [355].  
Further complicating the picture are recent findings suggesting that functional CB1Rs are not 
restricted to the plasma membrane but also expressed intracellularly, as exemplified in 
mitochondria where CB1Rs regulate neuronal energy metabolism (for a recent review on 
neuronal activity and mitochondrial CB1R see [356]). CB1Rs expressed in the outer membrane 
of mitochondria (mtCB1R) [357] are able to engage a signalling cascade via cyclic-AMP, PKA 
and complex I triggering neuronal respiration decrease and inhibition of memory formation 
[358]. Though the mechanistic details of mtCB1Rs were recently delineated [358], functional 
implications of mtCB1R signalling require further investigation. 
Peripheral CB1R expression within a variety of tissues has been extensively assessed [359-
363]. Only recently however, functional interactions between brain-controlled behaviours 
and peripheral eCB-mediated processes have been discussed. CB1R-mediated sympathetic 
activation was indeed shown to mediate hypophagia and anxiety like behaviours [364]. 
Furthermore, CNS-periphery CB1R-mediated signalling was shown to modulate stress 
hormone release from the adrenal medulla [365] and gut microbiota metabolism in obesity 
[366, 367]. 
1.3.2.4 Glia-neuron interplay regulates endocannabinoid actions 
Cannabinoid receptor expression in glial cells challenged the initial neuro-centric view of the 
eCB system. Moreover, though initial evidence suggested that CB1Rs selectivity localized to 
neurons while CB2Rs are restricted to glia, recent findings indicate a more heterogeneous 
distribution within cell types [368]. CB1R expression in astrocytes was shown to have a 
principal role in modulating neuron-glia interactions, able to regulate LTD and learning and 
memory [368, 369].  Mechanistically, this was found to be related to MAGL-mediated 2-AG 
metabolism [369]. Hence, CB1R modulation of synaptic plasticity has to be reconsidered, 
adding astrocyte-mediate signalling to the already described pre- and postsynaptic 
mechanisms. CB1R signalling has also recently been demonstrated in microglial cells [370] and 
in oligodendrocyte progenitors whose survival is enhanced by eCBs via Akt signalling [371]. 
CB1Rs, CB2Rs, DAGLα/β and MAGL are all expressed in developing oligodendrocytes and 
appear to be developmentally regulated [372], highlighting roles for 2-AG metabolism and 
signalling in oligodendrocyte progenitor development.  
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1.3.3 Endocannabinoids in the developing neurite 
In addition to serving as retrograde signals at adult synapses, eCBs also play critical roles in 
neurodevelopment. eCBs contribute to cell proliferation [373], migration [374], axonal 
outgrowth [375] and synaptogenesis [376]. The molecular mechanisms underlying these 
diverse roles of eCBs in the developing brain are area of intense research.    
1.3.3.1 Endocannabinoid signalling machinery in the foetal brain 
eCB machinery varies substantially throughout brain development and considerably differs 
from its adult counterpart. Endogenous 2-AG levels in rodents are relatively stable from the 
prenatal stage throughout adolescence and adulthood (2-8 nmol/g tissue), with a noticeable 
peak at birth [377, 378]. AEA levels are high at fertilization, followed by a strong intrauterine 
downregulation, important for embryonic implantation [379]. AEA is then detectable again 
from mid-gestation onwards, steadily increasing from the perinatal period (3-6 pmol/g) until 
adulthood [377]. Understanding the functional implications of these changes in AEA requires 
consideration of the varied eCB mechanisms of action within developing neurons and glia. In 
particular, immature developing neurons exhibit a unique cell autonomous (autocrine) eCB 
signalling mechanism, in contrast to the above-described paracrine eCB synaptic signalling. 
CB1R, CB2R, DAGLα and DAGLβ are all co-expressed within neuronal progenitors in the SV 
zone, consistent with an autocrine eCB signalling mechanism regulating asymmetric cell 
division [380, 381]. Furthermore, the eCB degrading enzymes MAGL and FAAH are highly 
expressed in radial glia [375] and progenitor cells [373]. Once progenitor cells differentiate to 
neuronal cells a CB2R to CB1R switch occurs, coincident with downregulation of DAGLα and 
DAGLβ, thus promoting cellular sensing of 2-AG concentration gradients to stimulate cell 
migration [380] (Figure 7).  
In mice, CB1R mRNA has indeed been detected in pyramidal cells of the cortical plate form 
E11.5, with a peak at E14.5 [374]. Moreover, at E12.5, cells in the subpial area of the GE, 
putative early interneurons, intensely label for CB1Rs [350]. These patterns of expression 
were also confirmed in human studies, which detected CB1Rs in the cortical plate at early 
stages of development (9–10 pcw) within radially oriented putative pyramidal cells, and in 
immature interneurons at early stages of cortical development (9–17 pcw) [382]. It is 
interesting to note that the subcellular localization of eCB receptors was cell type specific 
[376]. Moreover outgrowing axonal projections both in human and rodent transiently express 
CB1Rs that are downregulated after synaptogenesis [378].  
Changes in eCB enzymatic machinery expression profiles are also instructive for neuronal 
development, driving a switch from autocrine to paracrine signalling [381]. DAGLα and 
DAGLβ are co-expressed with CB1Rs at mid-gestation in the axonal shaft and growth cones of 
corticofugal migratory neurons [285]. MAGL expression was detected within central and 
peripheral axons as early as E12.5 [375]. Since CB1Rs and DAGLα coexist along the axonal 
shaft, 2-AG inactivation and sequential availability is determined by MAGL subcellular 
position. Indeed, MAGL is generally excluded from the growth cone during migration, when it 
accumulates in the axon stem, generating a decreasing gradient of 2-AG hydrolysis towards 
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the growth cone [375]. Once migratory neurons reach their target structures, eCB signalling 
further instructs the development of synaptic contacts. During synaptogenesis MAGL 
redistributes in the growth cone contributing to stop axonal growth by eliminating 2-AG 
signalling at the tips. Simultaneously, DAGLα localization switches from axonal to 
somatodendritic and postsynaptic, generating focal loci for 2-AG production, to signal 
through CB1R+ presynaptic terminals of GABAergic cells [285]. The adult synapse is therefore 
established with the characteristic presynaptic expression of CB1Rs and MAGL; while DAGLα 
localises at its postsynaptic counterpart [381]. This enzymatic machinery redistribution 
orchestrates a functional switch from autocrine to paracrine eCB signalling [381].  
 
 
Figure 7. Endocannabinoid signalling shifts form autocrine to paracrine along neuronal development. 
2-AG receptors and enzymatic machinery distribution differs substantially throughout different 
stages of brain development and synaptogenesis. (A) DAGL (magenta), MAGL (blue), CB1R (green 
receptor) CB2R (orange receptor) are co-expressed in neuronal progenitors, promoting cell 
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autonomous 2-AG (red circles) signalling and asymmetric cell division. (B) Once neurons exit the 
proliferation stage and start migrating, CB1Rs mainly characterize the developing neurite. Cell 
autonomous 2-AG signalling is still present at the beginning of neurite outgrowth, where CB1Rs 
mediate intracellular signalling leading to cytoskeleton modification and axonal outgrowth (for a 
comprehensive review on 2-AG-induced signalling via CB1R see [383]). MAGL is generally excluded 
from the growth cone. Accumulating along the axonal stem (not shown), MAGL generates a 
decreasing gradient of 2-AG hydrolysis towards the growth cone, essential for correct growth cone 
extension [375]. Along cell development DALG is gradually downregulated in the growth cone, 
favouring a paracrine signalling and migration along the 2-AG gradient generated by the target cells, 
expressing high levels of DAGLα and MAGL. (C) Once the growth cone reaches the postsynaptic 
target proximity, the endocannabinoid machinery further rearranges to mediate the correct pre- 
and postsynaptic compartments apposition. During synaptogenesis MAGL redistributes within the 
presynapse, limiting 2-AG availability and likely contributing to generate the stop signal for axonal 
outgrowth. At this stage DAGL is excluded from the presynaptic compartment and redistributes to 
its final location within the soma and the dendrites. Therefore at this stage 2-AG is provided 
exclusively by the postsynaptic target cell, that via paracrine signalling promotes synaptogenesis. 
(D) eCB signalling within the mature synapse is quite complex and varies depending on the type of 
cells engaged, mediating plasticity via multiple mechanisms. Here, depolarization-induced 
suppression of inhibition (DSI) is illustrated, one of the most studied eCB-mediated retrograde 
signalling events. Postsynaptic depolarization by excitatory inputs causes an increase of intracellular 
Ca++ by activation of voltage gated calcium channel (blue) via NMDA receptors and mGLU receptors. 
This excitation-induced cascade leads to 2-AG production, via DAGL in the postsynaptic 
compartment. Released 2-AG binds to Gi/o-coupled CB1Rs expressed on the GABAergic presynapse 
and inhibits Ca++-dependent GABA release, ultimate yielding DSI.  
 
1.3.3.2 The role of endocannabinoids in neurite outgrowth 
Numerous genetic and pharmacological approaches have confirmed a fundamental role for 
eCBs in axonal outgrowth, cell migration and target recruitment (Table 1). Exogenous 
cannabinoids applied in vitro can trigger CB1R internalization and downregulation from 
sensing structures such as filopodia, resulting in a collapsed growth cone and overall 
chemorepulsion [375]. Genetic ablation or pharmacological inhibition of CB1Rs leads to 
fasciculation defects of the major axonal tracts within the cortex [374]. Moreover, CB1R 
interneuron-specific downregulation resulted in a redistribution of inhibitory synaptic puncta 
in the adult cortex, representing a long-lasting failure in targeting cortical structures [376].  
Intracellular mechanisms involved in cannabinoid–induced axonal outgrowth were recently 
addressed, highlighting an indirect cannabinoid-cytoskeleton interaction [384, 385]. Both 
endogenous and exogenous cannabinoids were able to trigger CB1R coupling with G12/13 
proteins, leading to actomyosin-mediated cytoskeleton contraction via non-muscle myosin 
(NMII) through a Rho-GTPase and Rho-associated kinase (ROCK) [384]. This proposed 
intracellular mechanism results in rapid growth cone and neurite remodelling, increased 
cytoskeleton stability and an overall impairment of somatodendritic morphology [384].  
Using a proteomics approach, a second study proposed a similar mechanism in mouse cortex 
[385]. CB1Rs were shown to interact and regulate the activity of multiple members of the 
WAVE1 complex and the Rho GTPase Rac1 [385]. In this study, growth cone retraction was 
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induced via WAVE1 upon CB1R engagement, leading to growth cone collapse in developing 
neurons and spine remodelling in mature neurons [385]. Interestingly, a recent study 
suggests that the contribution of eCBs to axonal outgrowth is not solely mediated by CB1Rs, 
but also by CB2Rs [386]. CB2Rs were localized to the retino-thalamic pathway, specifically 
within axonal growth cones [386].  
Genetic and pharmacological modulation of CB2Rs induced growth cone reorganization via a 
cAMP/PKA pathway and impaired retino-thalamic pathway development [386].  DAGLα co-
expression with CB1Rs in the growth cone during axonal growth is required to promote 
axonal outgrowth, ensuring sufficient 2-AG availability [376].  Indeed genetic deletion of 
DAGLα impairs cortical projecting bundles [387].  
An example of the importance of eCB machinery localization is the developing 
thalamocortical bundle, characterized by an eCB-mediated “handshake” between 
corticothalamic and thalamocortical fibres [234, 375]. Thalamocortical axons lack CB1Rs and 
express MAGL, while corticofugal CB1R+ axonal tips lack MAGL. Corticofugal axons also 
express DAGLα and use the produced 2-AG both in a paracrine manner, to control 
fasciculation, and as autocrine signalling at the tips to promote axonal extension. The 
hydrolytic activity of MAGL+ within thalamocortical fibres limits 2-AG availability generating 
an eCB gradient responsible for the “handshake” mechanism via favourable migratory 
corridors [375].  
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Table 1. Untying endocannabinoids cobweb: a schematic summary of genetic and modulation studies. As 
described above, endocannabinoids are major players in axonal outgrowth. This table reports a schematic 
summary of genetic and pharmacological evidences supporting the importance of eCB and eCB machinery 
components in neuronal development. Modified from Maccarrone et al [381]. 
 
Model Observed phenotype 
CB1R-/- The first description of CB1R-/- mice detailed an increased mortality upon CB1R deletion, but 
no major developmental phenotype [388]. This idea was rapidly modified in follow up studies 
using conditional knockout mice, with migratory phenotypes and mistargeting of CB1R-/- 
interneurons [376], progenitor proliferation impairments [376, 389] and axonal fasciculation 
defects in CB1R-/-pyramidal cells [390]. 
CB2R-/- CB2R-/- mice showed abnormal eye-specific segregation of retinal projections in the dorsal 
lateral geniculate nucleus, demonstrating CB2R contributions to neuronal development [386]. 
DAGLα-/- DAGLα-/- mice revealed altered synaptic distributions in the hippocampus and axonal growth 
cone impairments [391]. 
GPR55-/- GPR55 genetic knockdown did not highlight any developmental anatomical axonal 
phenotype, rather inducing late-onset behavioural phenotypes, including memory 
impairment and depressive symptoms with major axonal phenotypes [392].  However a 
recent study assessed GPR55 modulation of growth rate of retinal projections using both 
GPR55-/-, lysophosphatidylinositol (LPI) and O-1602 administrations (GPR55 agonists) [393]. 
AM251 Results achieved by pharmacological in vivo modulation partially recapitulate receptor 
knockdown models. Perinatal AM251 (CB1R antagonist) injection was shown to affect critical 
period plasticity of the whisker map by mistargeting somatosensory axons of the barrel 
cortex [394]. 
SR414716 SR414716 (CB1R antagonist) intraventricular prenatal injection in mouse embryos negatively 
affects progenitor migration from the subventricular zone and recapitulates corticofugal 
phenotypes described in CB1R-/- mice [374]. 
WIN55,2122 Using the opposite approach, WIN55,2122 (CB1R and CB2R agonist) injection during 
pregnancy altered the migration of GABAergic interneurons and pyramidal cells as well as 
increased the number of migrating Cajal-Retzius cells along the MZ [395]. 
JZL184 MAGL inhibition consequences for development were addressed by JZL184 exposure (MAGL 
inhibitor). JZL184 acted as a functional antagonist causing an increase in available 2-AG and 
long-lasting effects on eCB receptor expression, with consequent axonal growth defects and 
impairments in cortical network formation [391]. 
URB597 Similarly to GPR55 genetic knockdown, URB597 treatment produced no major axonal 
phenotype, but did lead to long-lasting behavioural impairments [396]. 
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1.3.3.3 Endocannabinoids: key mediators of maternal programming 
The central role of eCBs in critical events during brain development is extensively highlighted 
by the findings listed above. However, whether maternal eCB imbalances during pregnancy 
are sufficient to trigger developmental deficits that precipitate neurological disorders 
remains poorly investigated?  
If so, blood-born circulating maternal eCBs could contribute to tonic embryonic eCB levels, 
while acute synthesis in specific foci of the developing brain would contribute to phasic 
localized eCB signalling. The foetal placenta represents not only an environmental barrier but 
also a key regulator of maternal-foetal interactions, as shown for nutrient transport, 
endocrine function and immune tolerance [397]. CB1R, CB2R and FAAH expression were 
recently assessed immunohistochemically and by mRNA levels in the human placenta and 
gestational membranes. Strong CB1R expression was found in amniotic epithelium, reticular 
cells and moderate expression was observed in chorionic cytotrophoblasts [398]. FAAH 
expression was highlighted in amniotic epithelial cells and trophoblasts [398] and exhibited 
temporal regulation throughout pregnancy, with peak mRNA levels observed at 11 pcw 
before declining [399]. CB2Rs were mainly localized within placental macrophages [399]. 
Clinical studies have confirmed strong correlations between decreased maternal circulating 
FAAH and early pregnancy success rate [400]. A separate study reported that significantly 
lower circulating levels of FAAH correlate with in vitro fertilization-embryo transfer failure 
[401]. Experimental models confirmed these finding, suggesting that low circulating FAAH 
activity is responsible for increased intrauterine AEA and consequent uterine refractoriness 
to blastocyst implantation [402, 403]. The above observations provide strong clues that 
maternal eCB machinery influences embryonic eCB availability.  
Active transportation via placenta has been assessed for water, electrolytes, glucose, 
cholesterol and PUFAs. Placental PUFAs transportation is regulated by several plasma 
membrane-located transport proteins that in turn are regulated by fatty acid-activated 
transcription factors [404]. It is therefore possible that metabolic derivatives of maternal 
long-chain fatty acids are transported to the intrauterine environment, where the foetus can 
use them as metabolic precursors of eCBs. Indeed fatty acid composition of the maternal diet 
during the first and the second half of gestation was shown to determine fatty acid 
composition of mothers’ milk and plasma, as well as fatty acid levels in offspring plasma 
[405]. Moreover, maternal dietary fat composition was repeatedly shown to alter fatty acid 
composition of cell membranes in the offspring brain [406-409]. Human ω-3 deficiency 
during gestation and lactation was shown to impair visual and cognitive functions in the 
offspring [410, 411]. Along the same line, ω-3 deficient diets reduce dopaminergic and 
serotonergic neurotransmission in rodent offspring [412, 413].  Moreover, maternal ω-6/ω-3 
ratios directly affect 2-AG levels in offspring hippocampus and hypothalamus altering eCB-
mediated inhibition of stress responses [414].  
Interestingly, eCBs in pregnancy may interact with maternal leptin hormone signalling. In 
adults leptin was shown to reduce appetite by inhibiting orexigenic neuropeptide [415] in the 
hypothalamus [416]. Circulating leptin was found to be increased in pregnant mothers [417] 
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and leptin receptors are expressed in mice embryos as early as E10.5 [418]. Leptin signalling 
is downregulated in the hypothalamus of offspring born to obese mothers due to decrease 
leptin receptor expression leading to compromised hypothalamic network development 
[419]. A role for eCBs in this story was introduced when leptin and leptin receptor in the 
hypothalamus were shown to regulate 2-AG and AEA levels, providing the first mechanistic 
connection between eCBs and leptin [416]. Potential leptin-induced eCB imbalances in the 
foetal brain due to maternal obesity remain an unexplored possibility, but would be 
consistent with observations that trans-placental leptin passage peaks coincident with 
synaptogenesis in rodents [420]. 
1.3.4 Endocannabinoids and neurodevelopmental disorders  
Both preclinical and clinical studies strongly support eCB involvement in several 
neurodevelopmental disorders [421-423]. Though the aetiology and symptomatic profile of 
such diseases are not detailed here, this section briefly highlights several described 
alterations of the eCB system within anxiety, mood disorders, schizophrenia and autism (for 
comprehensive recent reviews on the above illnesses see [424-427] respectively). Because of 
the neurodevelopmental nature of these disorders, an early intervention via eCB modulation 
might be beneficial, supporting the recently proposed preventive approaches for psychiatric 
and cognitive disorders [98].  
Common limitations of the clinical studies reported below are due to the nature of 
psychiatric disorders, which might explain complex and even contradictory results in different 
studies due to chronic versus absent medication, illicit substances use, post-mortem 
experimental methodologies and poor living conditions frequently experienced by these 
patients. Recent development of novel imaging techniques such as quantitative positron 
emission topography (PET) combined with the CB1R selective radioligand MK-9470, might 
partially overcome typical hurdles associated with post-mortem studies [428]. Moreover, a 
major difficulty in studying neurodevelopmental disorders is the typically delayed 
symptomatic stage. The vast majority of available literature on psychiatric diseases focuses 
on patients monitored after exacerbation of the disease. However, even if extremely complex 
to collect, it would be interesting to accumulate neurobiological data prior to symptom onset, 
during childhood and prenatal development of high-risk subjects.   
1.3.4.1 Anxiety  
eCB involvement in anxiety disorders is complex and only partially understood. Preclinical 
findings highlight both anxiogenic and anxiolytic effects upon cannabinoid agonist exposure 
[423]. Summarizing recent literature, cannabinoid agonists tend to reduce anxiety-like 
behaviours in low doses and increase them with high doses [423]. Local prefrontal cortex 
(PFC) increases in AEA signalling reduce anxiety with low doses of methanandamide (AEA 
analogue, metabolically stable) [429] and URB597 (FAAH selective inhibitor) [430]. High doses 
of methanandamide and URB597 mediate instead anxiogenic-like behaviour, an effect 
recapitulated by lentivirus-mediated FAAH over-expression in the PFC [423]. Anxiety-related 
effects upon 2-AG metabolism are less-well understood.  However, recent data suggests 
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effects similar to AEA based upon JZL184 administration [431]. The most exciting results 
emerged therefore from modulation of eCBs locally within the PFC. However, eCB regulation 
both in the ventral hippocampus [432] and in the dorsolateral periaqueductal gray [433] has 
been shown to control anxiety-like behaviours. 
1.3.4.2 Mood disorders 
Rimonabant (SR141716, CB1R inverse agonist) was introduced as an anorexic drug, and then 
quickly withdrawn due to side effects including the induction of depressive episodes and 
mood variation [434]. Therefore, if recreational cannabis is widely used for its 
euphoric/relaxing effect, CB1R block via rimonabant induced instead depressive episodes. 
Cortical CB1R expression alterations post-mortem have been identified in mood disorder 
patients [435], however the data are inconsistent across studies [423]. eCB levels and eCB 
machinery were found to be altered in a region-specific manner, with AEA and 2-AG 
increases in PFC [436] and higher FAAH activity in the ventral striatum [437] of depressed 
alcoholics compared to alcoholics without depression. Accordingly, pharmacological 
inhibition of FAAH enzyme reduced depressive-like behaviours in animal models [438]. 
Peripheral serum levels of AEA and 2-AG were significantly reduced in depressed patients, 
with an interesting negative correlation between 2-AG concentrations and length of the 
depressive episodes [439]. These findings could lead towards a future of personalized 
medical treatment for patients that present altered eCBs measured by blood samples [422]. 
Genetic screening in mood disorder patients revealed positive correlations between disease 
susceptibility and polymorphisms in CB1R and FAAH encoding genes [423]. Studies on eCB 
imbalances in bipolar patients remain rare and are so far not conclusive [422]. Interestingly, 
major depressive disorder patients display alterations in peripheral lipid availability [440], 
including decreases in ω-3 fatty acid derivatives. Consistently, a recent cohort exhibited an 
inverse relationship between ω3 fatty acid intake and depression, confirmed by lower 
depression scores associated with an ω3 rich Mediterranean diet [441].  
1.3.4.3 Schizophrenia  
Among the neurodevelopmental disorders discussed herein, schizophrenia is the pathology 
most closely linked with dysfunction of the eCB system [423]. Despite numerous early 
observations suggesting that cannabis use worsens schizophrenia or induces psychotic 
symptoms [442], there is no direct evidence that cannabis is either sufficient or necessary to 
induce the disease [443]. Interesting findings on disease aetiology came instead from studies 
of eCB levels in patients and animal models. Cerebrospinal fluid (CSF) levels of AEA were 
significantly elevated in a cohort of antipsychotic-naive first episode schizophrenia subjects 
[444], as well as in a cohort of subjects with prodromal psychosis [445] and an additional 
cohort of subjects with acute symptoms off-medications [445]. However, the implications of 
increased peripheral AEA for the CNS remain to be addressed. Moreover, altered eCB levels 
were reported in blood samples [446] and post-mortem brain tissues [423] of schizophrenic 
patients. 
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Dysfunctions of dorsolateral PFC layer 3 local networks are chiefly involved in schizophrenia 
[443]. Indeed, an excitatory-inhibitory imbalance within layer 3 PFC has been confirmed by 
numerous observations, including a significant decrease of PV-basket cell inputs on layer 3 
excitatory neurons in PFC of schizophrenic patients [447]. Moreover, the PFC of 
schizophrenic patients is characterized by lower PV mRNA and protein expression 
accompanied by an overall deficit in the GABA synthesizing enzyme glutamic acid 
decarboxylase 67 (GAD67) at mRNA and protein levels [443]. In addition Cck-basket cells have 
been recently proposed as active players in schizophrenia, based on observed reductions in 
Cck mRNA and protein levels in the PFCs of schizophrenic patients [448]. While DAGLα, 
DAGLβ, MAGL and FAAH levels remain unchanged in schizophrenic patients, ABHD6 mRNA 
levels were elevated in the PFC [443]. Interestingly, ABHD6 co-localize with DAGLα in 
dendritic spines of PFC excitatory neurons [288].  Thus, it was proposed that increased 
ABHD6 activity in schizophrenic patients could promote higher 2-AG metabolism at the foci 
of action, with a consequent reduction in 2-AG mediated activation of CB1Rs in Cck-basket 
cells [443]. This may be consistent with human studies reporting lower CB1R mRNA [423] but 
higher CB1R binding by radiolabelled ligands [449], possibly reflecting altered trafficking of 
CB1Rs upon decreased 2-AG availability (for a comprehensive review on eCBs-mediated 
inhibition impairment in schizophrenia see [443]). These observations suggest that 
pharmacological modulation of eCBs in the PFC could represent a valid novel opportunity for 
schizophrenia treatment. Indeed exciting results indicate that CBD is able to reduce negative 
symptoms in schizophrenic patients, possibly due to its ability to regulate AEA metabolism 
[423].  
1.3.4.4 Autism spectrum disorders 
eCB signalling in relation to autism spectrum disorders (ASD) has been recently reviewed 
[450]. Observed eCB-mediated regulation of emotional responses [451], context reactivity 
[452] and social interactions [453] in healthy subjects have suggested a possible involvement 
in ASD. Evaluation of eCB machinery in an ASD genetic model revealed dysfunctional 2-AG 
metabolism upon fragile X mental retardation (fmr1) gene knockout, together with decreased 
DAGL and MAGL activity [454]. Indeed, stimulating 2-AG metabolism restored synaptic 
activity in ASD models via type I metabotropic glutamate receptor activation [455]. Rat 
prenatal exposure to  valproic acid (VPA, mood stabilizer) provides an alternative 
experimental model for ASD [456] and recapitulates the above described DAGL and MAGL 
enzymatic imbalances [457]. AEA-mediated autistic-like behaviours were mechanistically 
examined recently, demonstrating altered CB1R phosphorylation in multiple brain regions, 
together with long lasting effects on FAAH and NAPE-PLD levels from infancy to adulthood in 
the VPA-ASD model [457]. Targeting AEA inhibition was therefore sufficient to rescue 
behavioural deficits of VPA-exposed rats [457]. Preliminary data also suggest CB2R, GPR55 
and PPAR involvement in ASD [450]. Moreover, plasma levels of unsaturated fatty acids are 
decreased in autistic patients [450], suggesting that supplement-based therapy may improve 
symptomology.  
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1.3.5 Prenatal cannabis exposure 
1.3.5.1 Maternal cannabis prevalence: a socio-geo-political perspective 
Reports on drug abuse highlight a noticeable State-to-State variability in cannabis 
consumption.  About 147 million people or 2.5% of the world population, use  cannabis at 
least annually, compared with 0.2% that consume cocaine and opiates [458]. A 2016 cannabis 
usage prevalence map of Europe depicted a heterogeneous scenario [459]. Cannabis 
prevalence was reported for all adults (15-64), young adults (15-34 years) and school age 
respectively, for UK (7%, 12%, 25%), France (11%, 22%, 39%), Spain (9%, 17%, NA), Germany 
(5%, 11%, 19%), Italy (9%, 19%, 21%), Austria (4%, 7%, NA), Netherland (8%, 16%, 27%), 
Hungary (2%, 6%, 19%) and Czech Republic (11%, 24%, 42%) [459]. European cannabis usage 
prevalence has remained stable within the last few years in certain countries (eastern and 
south-eastern Europe), decreased in others (Western and central Europe) and increased in a 
few (Bulgaria, Estonia, Finland and Sweden) [459]. The 2016 National Survey of Drug Use in 
the USA reported cannabis usage ranging from 10.4% (26 years-older) to 32.2% (18-26 years), 
with a 1% increase from 2013 to 2015 [460]. 
Global prevalence fluctuations are certainly affected by the mutable social and legal status of 
recreational cannabis consumption. Cannabis has historically been classified as an illegal 
narcotic drug in Europe from 1961 (United Nations single convention on narcotic drugs) and 
illegal under federal law in the United States, where it is classified as a Schedule I substance 
under the Controlled Substances Act of 1970. However, national autonomy on this matter 
has resulted in a very heterogeneous “legal map” for recreational cannabis. Legality of 
cannabis use is quite heterogeneous even within the US, with a recent update in November 
2016, when 8 sates fully legalized both recreational and medicinal marijuana (Alaska, 
California, Colorado, Maine, Massachusetts, Nevada, Oregon and Washington). The 
remaining states report decriminalized policy and often legalized medical use. The European 
portrait is also complex with variable legal positions for recreational cannabis, including: 1) 
tolerance for possession of small amounts intended for personal consumption (Belgium, 
Germany, Greece and Austria); 2) small amount consumption allowed only in “Coffee shops” 
(Netherlands) or “Cannabis Social clubs” (Spain); 3) administrative sanctions (Denmark, Czech 
Republic, Estonia, Ireland, Italy, Latvia, Luxemburg, Portugal, Slovenia, Croatia and Norway); 
and 4) penal sanctions (Cyprus, Hungary, Poland, Slovak Republic and UK) [459]. Medical 
cannabis approval is quickly spreading in Europe as well including cannabis plant smoking, 
whole plant extracts (Bedrocan or Nabiximols, trade name Sativex), and THC synthetic 
analogues (Nabilone and Dronabinol, marketed as Marinol and Cesamet) approved as anti-
nausea, antiemetic, antispasmodic, anti-inflammatory, anti-epileptic and analgesics [459].   
While global cannabis use, as for most of illegal drugs, remains more popular in males, 
alarming results are reported from cannabis consumption in females during pregnancy. A 
recent study reported a meta-analysis of cannabis consumption from the female cohort aged 
18 to 44 years of the annual National Survey on Drug Use and Health (NSDUH, 2002 to 2014).  
Among all pregnant women prevalence of past-month marijuana use increased 62% from 
2002 through 2014, rising from 2.37% in 2002 to 3.85% in 2014. Prevalence of past-month 
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marijuana use in 2014 was significantly higher in pregnant younger women (reaching 7.47% 
among those aged 18 to 25 years compared to 2.12% among those aged 26 to 44 years) 
[461].  Past-year cannabis use in pregnant women was even higher, reaching 11.63% in 2014 
[461]. Non-pregnant women counterpart prevalence was higher compared to pregnant, 
reaching 9.27% for past-month use and 15.93% for past-year use in 2014 [461]. Illicit drug 
abuse during pregnancy negatively correlated with age, rising to 18.3% amongst pregnant 
women aged 15-17 [462].  
1.3.5.2 Complications: THC is not alone 
Cannabis sativa is interestingly unique in its ability to synthesize a vast family of cannabinoids. 
THC, though exhibiting the greatest psycoactivity, is one of 70 other compounds identified in 
cannabis plant [459].  The very different pharmacology of CBD results in a non-psychoactive 
action [463]. Due to CBD antipsychotic properties [464], THC/CBD ratio affects the overall 
psychoactive potential, leading to high side effects if cannabis contains high levels of THC 
over CBD [465-467]. THC and CBD content were recently compared between Netherlands, 
England and USA between 2003 and 2005, highlighting high variability of THC%/CBD% 
depending mainly on  the commercial form (Netherlands: sinsemilla 20.4%/0.2%, herbal 
7.0%/0.2%, resin 18.2%/8.1%; England: sinsemilla 14.0%/0.1%, herbal 2.1%/0.1%, resin 
3.5%/4.2%; USA: sinsemilla 11.2%/0.2%, herbal 5.0%/0.5% and resin 9.2%/3.9%)[459]. These 
numbers represent a noticeable change compared to THC/CBD ratios in traditional Moroccan 
plants used to make traditional hashish (resin) which are closer to 2:1 and resin from 
countries such as Nepal and Kashmir, having an approximately equal THC/CBD ratio [459]. 
UNODC’s World drug report highlighted increasing concerns over the rising popularity of 
potent CBD-free high-THC sinsemilla [466], obtained by allowing only females plants to 
blossom. 
1.3.5.3 Synthetic cannabinoids and Smart Drugs: a dangerous new fashion  
Synthetic cannabinoids, often referred as “legal high” or “smart drugs”, are a large group of 
new psychoactive substances, available on the market since the mid-2000s, that mimic THC 
effects and bind to cannabinoid receptors [468].  Damiana (Turnera diffusa) and Lamiaceae 
herbs such as Melissa, Mentha and Thymus are commonly used as an herbal base for the 
smoking mixtures, on which the synthetic cannabinoids are mixed or sprayed [468]. The first 
synthetic cannabinoid JWH-018, sold under the brand name “Spice”, was detected in 
Germany and Austria in 2008 [459]. The number of detected synthetic cannabinoids on the 
market by December 2015 increased to 160 [468]. “Legal highs” thus represent a popular 
new fashion, characterized by limited data on use prevalence [469] and no available data on 
long and short term risks [470]. The US Monitoring the Future survey of students suggested 
5.8 % synthetic usage prevalence in 2014 for 17-18 years old [468]. Similar percentages were 
reported by a German study on smoking mixtures and “Spice” among students aged 15–18 in 
Frankfurt [468].  Concerns on harms related to synthetic cannabinoids are mainly due to the 
unknown possible side effects, alternative mechanisms of action and manufacturing 
processes [468]. A peculiar feature of synthetic cannabinoids is their ability to cause mass 
poisoning. As an example, the cannabinoid Fubinaca was linked to more than 600 poisonings 
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in Russia in 2014, resulting in 15 deaths; 200 hospital emergencies reported in Poland in 2015 
within less than a week; and  33 persons hospitalized in New York City in one night in 2016 
[468, 471]. 
1.3.5.4 Prenatal cannabis: evidence from human longitudinal studies 
Richardson and colleagues propose a “double hit hypothesis” for prenatal marijuana 
exposure [472], with maternal cannabis abuse delivering a “first hit” causing an eCB 
imbalance in the foetal brain, compromising neuronal network establishment in a way that a 
“second hit” may cause specific phenotype development [473]. The surprisingly high 
cannabis usage prevalence amongst pregnant women, together with the increasing THC 
strength in market compounds and the rapidly increasing availability of synthetic 
cannabinoids, raises the urgency to address the consequences of prenatal exposure to 
cannabis [473].  
Though the molecular mechanisms of prenatal cannabis are not clear, clinical observations 
from three prospective longitudinal human studies have been recently reviewed [473]. The 
Ottawa Prenatal Prospective Study (OPPS) was initiated in 1970 by Fried and colleagues 
[474]. It included 300 white, low-risk middle class women who self-reported at least six 
cannabis joints a week before and during pregnancy [474]. OPPS offspring were followed up 
to 22 years old [475, 476]. The homogeneity of the OPPS cohort study might be taken both as 
an advantage, being a consistent low variability group with high cannabis use, as well as a 
disadvantage since the study focused on a low-risk population with limited stressing factors 
and genetic variance, and thus limited potential for any eventual “second hit” in offspring 
later in life. The OPPS study reported decreased birth weight, increased startles and tremors 
and reduced habituation to light 48h after birth [474].  By the age of 3-4 years cannabis 
exposure correlated with impaired verbal and memory functioning [477]. Externalizing 
behaviours (i.e. hyperactivity, inattention and impulsive symptoms) significantly increased in 
cannabis exposed children at the age of 6 [478].  Additionally, by the age of 6 the OPPS study 
reported an impaired problem-solving ability in situations that required integration of 
visuoperceptual skills [478]. 18-22 year old young adults confirmed long lasting deficits during 
visuospatial working memory tasks [475], decreased response inhibition and impaired 
executive functioning assessed by fMRI [476] in cannabis exposed subjects.  
In 1982 the Maternal Health Practices and Child Development Study (MHPCD) was initiated 
[479]. The MHPCD study focused on high-risk woman, including over 500 mixed-race, mostly 
single, low socio-economic status woman [479]. The MHPCD cohort was divided by marijuana 
use during pregnancy into light (less than 3 joints per week), moderate (3 to 7 joints per 
week) and heavy users (more than one joint per day) [474], with offspring followed up until 
14 years old. MHPCD neonates presented an altered EEG recording during sleep [479]. 
Additionally, growth, sensory/perceptual responses, memory and learning parameters were 
affected within 1 year of age [479]. The MHPCD study confirmed the results obtained by the 
OPPS cohort, reinforcing the idea of impaired memory function and decreased verbal scores 
by the age of 3-4 years, adding an increased tendency towards anxiety and depressive-
related behaviours in cannabis exposed offspring [480]. By the age of 10 the MHPCD 
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offspring cohort exhibited significant impairments in abstract and visual reasoning [481], 
together with an increased incidence of depression, impulsivity and delinquency [481, 482].  
More recently Hofman and colleagues started the Generation R study, a large scale 
longitudinal study initiated in 2001 that is still ongoing, aiming to follow up more than 10,000 
multi-ethnic urban children from foetal development until adulthood [483]. The Generation R 
study is therefore the first longitudinal study to include data on prenatal conditions for 
offspring born from cannabis users. Numerous significant impairments were reported in the 
cannabis exposed foetuses, including reduced growth and head circumference, placental 
resistance, increased pulsatility and resistance index of the uterine artery, possibly underlying 
the decreased weight and length of neonates [484]. The impairments reported at 3 years by 
OPPS and MHPC were not measured in the Generation R study which instead reported 
increased aggression and inattention at this age in girls [483].  
Even if Generation R results on young adults are not available yet, numerous considerations 
have to be made when comparing the above studies. Cohort sampling was variable within the 
different studies, including socio-economical and ethnical heterogeneity and cannabis 
assumption quantities [472, 473]. Moreover, while OPPS and MHPCD studies took place from 
1970s to 2000s, the Generation R study involves cannabis products available later in the 
market, with a likely increase in strength and THC/CBD ratio [472]. These inevitable 
complications can be simplified by future research in animal models where species and 
amount of exogenous cannabinoids can be controlled, in order to dissect networks 
responsible for the cognitive impairments highlighted by human studies.  
1.3.5.5 Molecular mechanisms of transgenerational cannabis exposure 
The CB1R is the major target of THC [247], with potential minor signalling contributions 
through  CB2Rs [485] and GPR55 [486].  Importantly, THC cannot be degraded by endogenous 
MAGL, or any other endocannabinoid-related catabolic enzyme known to date. Thus, 
introduction of THC to developing foetal circuits could result in ectopic CB1R engagement, 
leading to unwanted directional neurite outgrowth and synapse formation errors [487]. 
Synthetic cannabinoid studies suggest that chronic cannabinoid agonist exposure causes 
CB1R down-regulation and rapid desensitization in a regionally distinct manner [488]. In sum, 
in utero THC is potentially able to reshape endocannabinoid signalling by directly affecting 
receptors and enzyme levels.  
Most transgenerational studies on animal models aiming to elucidate molecular mechanisms 
of cannabis in the developing brain uniquely analysed the effect of THC administration. 
However, one of the first studies on perinatal cannabis addressed α1-adrenergic and D2-
dopaminergic receptors in the offspring brain upon perinatal administration of both THC and 
CBD separately [489]. Several genes were found to be significantly altered in succeeding 
studies. Opioid peptide precursors, including prodynorphin, POMC gene expression and 
proenkephalin mRNA were altered in several brain regions of rat foetuses prenatally exposed 
to THC [490]. Neural adhesion molecule L1 expression was significantly increased after 
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prenatal THC exposure in CB1R+ axonal tracts in fimbria, stria terminalis, stria medullaris and 
corpus callosum [491] 
Prenatal THC exposure precipitated persistent behavioural deficits in the adult offspring. 
Long-term behavioural effects such as rearing, grooming and sniffing, were altered in the 
adult offspring of both sexes upon perinatal exposure [492]. The same study showed that 
THC-exposed males exhibited increased exploratory behaviour in a plus-maze paradigm 
[492]. Hypothalamus-pituitary-adrenal (HPA) axis activation was also evaluated after prenatal 
cannabis exposure, revealing higher hypothalamic levels of both corticotropin releasing 
factor (CRF-41) and corticosterone in females [492]. THC-induced dimorphic motor deficit 
was observed in a later study that proposed increased presynaptic dopamine D2 receptor 
sensitivity as an underlying cellular mechanism [493]. Prenatal cannabis exposure increases 
heroin seeking with allostatic changes in limbic enkephalins in adulthood. [494]. Interesting 
results are provided by a recent study that combined conditional CB1R strategies and 
prenatal exposure to cannabinoids. Using this strategy the investigators confirmed that THC-
induced long-lasting consequences in adult offspring are solely mediated by its ability to 
disrupt CB1R signalling during neurodevelopment [495]. 
Pioneering a series of studies examining  cell subtype selective involvement in mediating 
prenatal THC exposure deficits, the Fernandez-Ruiz laboratory described altered tyrosine 
hydroxylase gene expression and activity during early brain development [496] followed by 
postnatal impairment of tyrosine hydroxylase-containing neurons in rats [497]. Prenatal 
cannabis-mediated impairment was not limited to neuronal cells, but also described in 
astrocytes and Bergmann glial cells in the rat cerebellum. Prenatal THC caused deleterious 
effects on astroglial maturation, resulting in reduced glial fibrillary acidic protein and 
glutamine synthetase expression [498]. 
The first effort to correlate cell type specific impairments and long-lasting behavioural deficits 
provided correlative evidence of enduring cognitive deficits, cortical gene expression and 
neurotransmission in rats, reporting long lasting THC-induced alterations especially on 
glutamatergic and noradrenergic systems [499]. The most interesting evidence of a cell type 
specific engagement upon prenatal cannabis exposure was recently reported by Vargish and 
colleagues [500]. Maternal treatment with THC induced a significant reduction of Cck 
interneurons in the offspring hippocampus [500]. Furthermore, residual Cck interneurons 
displayed decreased dendritic complexity and compromised feedforward and feedback 
inhibition, possibly responsible for long-lasting impaired social behaviour in animals 
prenatally treated with THC [500]. 
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Summarizing, eCBs play major roles in neural development and networks establishment. 
CB1R, as well as eCB enzymatic machinery expression and subcellular compartmentalization, 
were shown to be fundamental for neuronal pathfinding and major axonal tracts 
development. In utero genetic and pharmacological eCB manipulation indeed perturbs axonal 
targeting, potentially leading to long-term networks impairment. Numerous studies 
confirmed that supra-physiological levels of 2-AG during development and in utero exposure 
to THC, are both able to affect protein and gene expression, impair the development of 
specific subpopulation of neurons and induce long-lasting behavioural deficits in the 
offspring. However, molecular mediators of eCBs crucial role in neuronal development 
remain largely undescribed. 
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2 AIM 
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The overall aim of this work was to investigate molecular determinants of endocannabinoid-
mediated brain development. Major effort was invested in detailing CB1R-mediated growth 
cone extension and eCB roles in the development of axonal bundles and network assembly. 
 
Study I aimed to interrogate upstream signals and molecular effectors of eCB machinery 
within foetal cholinergic projection neurons. 
Study II aimed to describe the role of eCB signalling in regulating oligodendrocyte-growth 
cone interactions during axonal bundle extension in the embryonic brain. 
Study III aimed to reveal molecular determinants and neuronal responses to in utero cannabis 
exposure and examine long-lasting circuit impairments induced by prenatal THC 
treatment.   
Study IV aimed to generate a comprehensive prenatal characterization of cholecystokinin-
containing GABAergic cells, the interneuron population with the highest CB1R 
expression and therefore potentially most sensitive to perinatal eCB imbalances. 
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3 RESULTS & DISCUSSION 
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3.1 Study I. Nerve growth factor scales endocannabinoid availability by regulating MAGL 
turnover in developing cholinergic neurons 
The majority of studies on eCB contributions to axonal guidance have focused on the 
neocortex [234, 375, 376], leaving potential roles in subcortical territories uncharted. 
Subcortical cholinergic projections to the neocortex express CB1Rs [268] and release 
acetylcholine upon CB1R agonist stimulation [193]. NGF promotes cholinergic neurons 
survival in the basal forebrain [188], synaptic connectivity [501] and rescues 
neurotransmission in diseased cholinergic neurons [502]. Adult cholinergic neurons of the 
basal forebrain where shown to express CB1R [268] and release acetylcholine in eCB-sensitive 
manner [193]. However, a potential coordinated action of NGF and endocannabinoids in 
promoting cholinergic axonal development has not previously been investigated. 
3.1.1 Endocannabinoid-mediated axonal development in foetal cholinergic projections  
In study I we detailed the expression of CB1R mRNA in subcortical territories at early 
embryonic ages by in situ hybridization. Medial septum (MS) was remarkably enriched for 
CB1R mRNA from E14.5 until birth. At E18.5 genetically tagged ChAT+ neurons highly 
expressed CB1R protein in cell bodies and along leading processes within the MS, the 
developing hippocampus and the corpus callosum.  
Committing to a systematic in vitro study, we detailed the differential localization of 2-AG 
enzymatic components within foetal cholinergic neurons. While MAGL expression was 
restricted along the VAChT+ primary neurite, CB1Rs and DGLα/β were identified at the distal 
dendrites and in the growth cones, suggesting cell-autonomous 2-AG signalling. In order to 
explore the functional role of CB1Rs in cholinergic neuron maturation, we assessed cell fate 
and morphology upon genetic and pharmacological CB1R manipulation. 
CB1R-/- and AM251-treated foetuses (3mg/kg, i.p.) both presented an unusual ectopic 
localization of low-affinity p75NTR in cholinergic neurons of the dorsolateral striatum at E18.5. 
Sholl analysis of septal VAChT+ neurites at the same age revealed an increased neurite 
complexity in CB1R-/- and AM251-exposed foetuses. CB1R loss of function was therefore 
sufficient to disrupt neuronal morphology of ChAT+ neurons during development, a possible 
primum mobile of the increased number of striatal cholinergic neurons in CB1R-/- adult mice. 
In order to probe for a potential permanent misrouting of long-range cholinergic projections 
in CB1R-/- mice, we examined the integrity of the septohippocampal ChAT+ pathway in CA1. 
CB1R-/- mice exhibited a significant reduction of cholinergic processes within the pyramidal 
layer and an overall decrease of MAGL immunoreactive putative presynaptic compartments 
in the same region of the hippocampus.  
3.1.2 NGF regulates cholinergic neurite outgrowth, compartmentalizing 2-AG degradation 
through sequential regulation of BRCA1 and MAGL 
In order to test our hypothesis of a coordinated action of NGF and endocannabinoids on 
cholinergic neuron development, we coincidently targeted CB1Rs and NGF high affinity 
receptors, TrkAs, in neuronal cultures. NGF alone was able to trigger neurite outgrowth and 
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induce the formation of multiple secondary VAChT+ processes. However, if combined with O-
2050, a silent CB1R antagonist, NGF was unable to drive increased neurite development. 
Thus, NGF-induced neurite outgrowth requires CB1R activation.  
NGF treatment in vitro induced a redistribution of the 2-AG enzymatic machinery along 
cholinergic neurites, resulting in an overall up-regulation of CB1Rs, DGLα, and MAGL proteins 
along with increased 2-AG concentrations. Interestingly, the pharmacological inhibition of 
TrkA signalling significantly reduced neurite outgrowth and redistributed MAGL towards the 
growth cone, revealing an NGF-mediated compartmentalization of 2-AG degradation.  
NGF-mediated MAGL overexpression was stabilized by proteasomal inhibition through 
lactacystin. Amongst proteasome ubiquitin ligases, breast cancer 1 susceptibility protein 
(BRCA1) was particularly attractive: BRCA1 was highly expressed during development in 
ChAT+ neurons in the basal forebrain and preferentially located at the leading processes of 
cholinergic neurons. Proceeding with a subcellular analysis, we confirmed a close apposition 
of BRCA1 and MAGL in motile neurites and growth cones, suggesting a possible direct 
molecular interaction. Our hypothesis was confirmed by exposing basal forebrain neurons to 
cisplatin, a platinum-based anticancer drug able to functionally inhibit BRCA1 activity. 
Cisplatin application on NGF-treated cholinergic neurons in vitro was sufficient to inhibit 
neuronal outgrowth and MAGL compartmentalization. 
Summarizing, in study I we reveal NGF signalling at TrkA receptor as a domain-specific 
molecular regulator of axonal outgrowth, via MAGL segregation in cholinergic neurons.  
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3.2 Study II. Endocannabinoids modulate cortical development by configuring Slit2/Robo1 
signalling  
CB1R and eCB enzymatic machinery distribution are fundamental for axonal fasciculation and 
a proper development of major axonal tracts. However, axonal pathfinding is one of the most 
delicate processes during brain development requiring exquisite coordination of a plethora of 
timed events [374, 384, 387] including the expression of specific guidance proteins. Amongst 
chemorepellant molecules mediating neuronal migration, Slit/Robo signalling represents a 
major phylogenetically conserved mechanism [194]. Although previous studies emphasized a 
Robo-/- commissural tract phenotype [196] and Slit1-/-/Slit2-/- comparable corticothalamic-
targeting defects [202], possible interactions between eCB and Slit/Robo machinery remain 
unexplored. 
3.2.1 JZL184 enhances 2-AG signalling in the foetal forebrain inducing an axonal 
fasciculation phenotype via MAGL inhibition  
Aiming to selectively enhance endogenous 2-AG signalling, we administered JZL184 (MAGL 
inhibitor, 40 mg/kg i.p.) to pregnant mice form E12.5 to E18.5. While other eCB levels 
remained unaffected by JZL184 administration, 2-AG content significantly increased in 
mothers and foetal brains. Pharmacological MAGL inhibition by JZL184 exposure was 
sufficient to provoke an enlargement of L1 neuronal cell adhesion molecule (L1-NCAM)-
expressing axonal fascicles, regardless of their projection target, leading to fasciculation of 
the corticothalamic/thalamocortical axons and significantly increased axonal spread in the 
corpus callosum. Immunohistochemistry revealed that these axonal phenotypes correlated 
with altered distributions of radial glial cell marker-2 (RC2) and brain1 (Brn1)+ pyramidal cells. 
Moreover Neurocan, a proteoglycan essential for cell adhesion [503], was excluded from 
thickened axonal fascicles in JZL184 exposed brains. A potential confounding influence of 
CB1R desensitization was excluded by acute in vitro experiments on cortical neurons 
pretreated with JZL184 for 4 days. Hence, the supra-physiological 2-AG levels likely promoted 
CB1R-mediated axonal fasciculation. 
3.2.2 CB1R+ misrouted axons accumulate Robo1 and host excessive end-feet proliferation 
of CB2R-expressing oligodendrocytes    
Oligodendrocytes are highly present within the corpus callosum bundle and are postnatally 
crucial for myelination [504]. Though the expression of CB1Rs and CB2Rs in oligodendrocytes 
has been described [371, 372], their functional role in eCB-mediated neurodevelopment has 
not yet been investigated. Upon JZL184 exposure, we observed a premature differentiation 
of oligodendrocytes amongst axonal bundles, confirmed by an increased number of their 
2’,3’-cyclic-nucleotide 3’-phospodiesterase (CNPase)+ end-feet apposing neighbouring axons. 
This JZL184-induced premature end-feet proliferation phenotype was observed in both WT 
and CB1R-/- axonal bundles, suggesting a mechanism involving CB2Rs within oligodendrocytes. 
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3.2.3 JZL184 induces growth cone chemorepulsion via Slit/Robo signalling.  
Analysing sections from human foetuses at gestational week 20-23, we highlight the co-
expression of CB1R and Robo1 within the same axons in the internal capsule. Upon JZL184 in 
vitro treatment, cortical neurons showed increased expression of Robo1 in the growth cone, 
in an O-2050 sensitive manner, confirming CB1R involvement. Robo1 accumulation within the 
growth cone was confirmed both pharmacologically on synaptosomes and by MAGL acute 
silencing in vitro.  
Pathophysiological significance of Robo1 accumulation in the growth cone upon supra-
physiological 2-AG levels was notably validated in human foetal subjects in utero exposed to 
cannabis. An increased Robo1 receptor mRNA was quantified in cannabis-exposed subjects, 
relative to controls. Remarkably, mRNA analysis of the human foetal cortex highlights a 
significant correlation between the expression of Robo1 mRNA and Slit1 regardless of 
cannabis exposure, furthermore suggesting a Robo/Slit functional interaction. Human results 
therefore reinforced our hypothesis that oligodendrocytes prematurely differentiate upon 
excessive 2-AG exposure, mediated by an overexpression of Slit at the end-feet in a CB2R-
dependent manner. Using oligodendrocytes in vitro as a model, we confirmed 
oligodendrocytes as a main source of Slit2. Hence, upon JZL184 exposure, oligodendrocytes 
recapitulated the in vivo phenotype, showing premature differentiation, and increased 
submembranous expression of Slit2 that accumulated at the end feet. Neuron-
oligodendrocyte co-culture experiments revealed that upon overexpression of Slit2 by 
oligodendrocytes, nearby neurites increased distance to apposing glial surface in a Robo1-
dependent manner. The JZL184 effect on oligodendrocytes was reversed by AM630, a CB2R 
antagonist, further supporting an “axonal pathfinding bipartite model” in which 
oligodendrocytes turn into active players, able to sense eCBs through CB2Rs and actively 
interact with Robo1-expressing growth cones. In sum, our findings from study II identified 2-
AG as an upstream signal molecule able to recruit Slit/Robo interactions in the process of 
axonal pathfinding (Figure 8).  
 
 
Figure 8. e modulates growth cone behaviour via Slit2/Robo1 signalling. 
(A) Schematic overview of eCB-mediated neurite outgrowth via glia-
growth cone interaction. (B) Supra-physiological levels of 2-AG modulate 
growth cone directionality configuring the downstream Slit2/Robo1 
interaction. Adapted from Study II, figure 8 [505].  
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3.3 Study III. THC exposure impairs cortical development via SCG10 degradation  
The startling incidence of cannabis use during pregnancy, which is likely to be exacerbated by 
recent depenalization policies around the world, demands further investigation into the cell, 
molecular, and circuit consequences of in utero exogenous cannabinoid exposure on foetal 
nervous system development. To investigate the molecular details of the signalling cascades 
involved upon maternal THC exposure during pregnancy we first had to establish an accurate 
mouse model. We administered THC daily at 3 mg/Kg (i.p., from E5.5 to E17.5) [506] which 
did not affect maternal behaviour, bodyweight, offspring size or sex ratio indicating that we 
were below threshold for intoxication that can occur with high doses [507]. Male foetuses 
where probed before birth (E18.5) using anatomical and molecular assays. Postnatal anatomy 
(postnatal day (P)-10 and P120) and electrophysiology (P120) were examined to probe for 
any potential long-lasting developmental deficits. 
3.3.1 THC affects axonal development and cortical network establishment 
THC exposed offspring showed significantly decreased CB1R+ perisomatic inputs within the 
superficial layer I/II of the cortex at both P10 and P120. This observation is similar to findings 
in interneuron-specific CB1R-/- mice [376] and is also consistent with a recent study showing 
significant loss of CB1R-expressing Cck-interneurons in the offspring of THC exposed mothers 
[508]. In addition, THC treated offspring displayed long-term functional modifications of 
hippocampal circuitry with altered synaptic activity at Shaffer collateral inputs to CA1. 
THC-exposed foetuses analysed at E18.5 displayed an impairment of axonal bundle formation 
in the corticofugal system, resembling the well-characterized phenotype of CB1R-/- mice [374]. 
THC significantly increased the diameter of the first order fascicles compared to vehicle 
controls. Administration of AM251 (5 mg/kg; CB1R antagonist), but not WIN55,212-2 (5 
mg/kg; CB1R agonist) showed a similar phenotype, suggesting CB1R signalling impairment is 
responsible of the corticofugal tract fasciculation phenotype. mRNA and protein analyses 
confirmed involvement of the eCB system, showing reduced CB1R levels and increased MAGL 
expression in the embryonic cortex upon THC exposure.  
3.3.2 Unbiased proteomics reveals THC-mediated reduction of SCG10 levels 
In order to identify the molecular effectors of THC-induced alterations we performed 
quantitative proteomics on cortices from male foetuses at E18.5 through isobaric tagging for 
relative and absolute quantification (iTRAQ). Peptides were analysed both by LC-
MALDI/MS/MS and nLC-ESI/MS/MS mass spectrometry to profile THC-sensitive proteins. Out 
of 837 identified hits, the expression levels of 35 proteins changed significantly upon THC 
treatment. Amongst differentially expressed proteins, SCG10/stathmin-2, a microtubule-
binding protein in axons, was exceptionally appealing given that SCG10 is highly expressed 
during corticogenesis and co-labels with CB1Rs in long-range projections and growth-cone 
structures. Proteomic analysis revealed that SCG10 levels were reduced upon THC and these 
findings were confirmed at both protein and mRNA levels.  
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3.3.3 THC induces axonal SCG10 degradation via proteasome, induced by JNK1 
To dissect the molecular cascades underling SCG10 degradation in vivo upon THC maternal 
administration, we availed of both in vitro and ex vivo models. Our in vitro data revealed that 
THC rapidly induces JNK and Erk1/2 phosphorylation in a CB1R-dependend manner, driving 
SCG10 proteasomal degradation in cultured cortical neurons. In order to confirm THC-
induced SCG10 degradation within an intact corticofugal projection system, we established 
an ex vivo model of our in vivo experimental protocol, using 300 µm organotypic slices from 
E14.5 forebrains to test the effects of THC treatment (10 µm, 30 minutes) on axonal SCG10 
distribution. Acute THC treatment was sufficient to diminish SCG10 expression in organotypic 
slices as measured by both SCG10 fluorescence intensity and spatial extent. SCG10 acute 
degradation in corticofugal axons was significantly attenuated by applying SP600125 (JNK 
inhibitor).  
To ascertain the relevance of our findings to the human nervous system, we probed SCG10 
expression in foetal human hippocampi from of electively aborted second trimester foetuses 
exposed to cannabis and compared them to age-matched controls. Hippocampal SCG10 
mRNA and protein expression was significantly reduced in cannabis-exposed subjects. 
Altogether, in study III we identified SCG10 as a molecular effector acting downstream from 
THC activation of CB1Rs that leads to long-lasting synaptic miswiring during foetal 
corticogenesis. Raising further concerns about marijuana consumption during gestation, 
findings from a recent study show that THC-exposed offspring exhibit persistent loss of Cck+ 
interneurons accompanied by deficits in feedforward and feedback inhibition in CA1 and 
altered social behaviour [500]. Cumulatively, recent findings reinforce caution against even 
mild cannabis use during pregnancy. 
 
 
Figure 9. Schematic representation of THC downstream pathway highlighted 
in Study III. In utero THC exposure engages CB1Rs and induces sequential 
phosporilation of JNK1. This results in SCG10 phosphorylation and 
degradation via proteasome. Adapted from Study III, figure 5 [509]  
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3.4 Study IV. Prenatal portrait of cholecystokinin-containing interneurons 
CB1R-expressing Cck-containing GABAergic interneurons [350, 510] were identified as an 
early neuronal population originating in the CGE [350, 511]. As shown recently by Vargish and 
colleagues [500], developmental anomalies driven by eCB (or phytocannabinoid) imbalances, 
chiefly affect Cck-CB1R-expressing interneurons. Prenatal characterization of Cck+ 
interneurons is however limited, mainly due to difficulties in visualizing them histochemically. 
Máté and colleagues recently developed a new transgenic mouse strain that expresses the T3 
variant of the Discosoma Red Fluorescence Protein under control of the Cck promoter 
(DsRedT3/Cck) [512]. Taking advantage if this mouse line, we examined the spatiotemporal 
profile and physiological maturation of Cck-expressing interneurons during foetal brain 
development. 
3.4.1 Methodological considerations: cell-specific transgene expression in the DsRedT3/Cck 
mouse brain 
Aiming to characterize the developmental trajectory of Cck+ interneurons we examined 
CckBAC/DsRed cells at E12.5, E14.5, E16.5/E18.5 and P20 focusing on: i) distribution in the whole 
brain by lightsheet microscopy; ii) molecular identities using immunofluorescence; and iii) cell 
morphology and excitability using patch-clamp electrophysiology with dye filling of individual 
cells. Mouse line Tg1 (~1 copy insertion of CckBAC/DsRed) and mouse lineTg47 (additional 
insertion of more copies ~7) [512] presented differences in fluorescence intensity, but 
displayed comparable cell distributions resembling previously described Cck+ cell distribution 
patterns [513, 514], including that described in the Allen Brain institute database mRNA map. 
In order to confirm the selectivity of DsRed expression in the DsRedT3/Cck adult mouse brain, 
we used a combination of in situ hybridization and immunohistochemistry. The vast majority 
of the DsRedT3 transgene-expressing cells co-localized with Cck mRNA. In order to selectively 
visualize GABAergic/DsRed+ cells, we generated a dual reporter mouse line co-expressing 
DsRed in Cck+ neurons and GFP in GABAergic interneurons (CckBAC/DsRed::GAD67gfp/+).  
3.4.2 Migratory pathway of DsRed+/CR+/CB1R+ interneurons in the forebrain 
Despite numerous postnatal studies on Cck interneurons, the ontogeny of Cck expression in 
the brain during gestation is poorly understood. Early prenatal Cck expression was observed 
previously in a subpopulation of neural tube and neural crest cells in mouse embryos (E8.5–
E9.5) [515], in olfactory sensory neurons [516], and in the thalamus and spinal cord at E12.5 
[514]. However, the in situ approach used in those studies to identify Cck-expressing cells, 
precludes additional levels of characterization, such as physiological interrogation or cell 
migration assays. Using the DsRedT3/Cck line, we developed a spatiotemporal map of Cck-
positive cell distributions at E10.5, E12.5, E14.5 and E18.5. Moreover, a modified Cubic-2 
clearing protocol [517] combined with light sheet microscopy was used as an innovative and 
powerful tool to visualize all the originating niches of Cck-expressing cells in the intact brain. 
The first niche of Cck+ interneurons leaving the CGE was visualized at E12.5 migrating along 
the tangential migratory stream (TMS). A large portion of those migrating Cck+ neurons 
showed coexpression of Calretinin (CR) (19.5 ± 1.2 %) at E12.5, similar to the 10-30% co-
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localization expected in the adult [518]. By E14.5 the majority of DsRed+/GFP+ interneurons 
migrated along the TMS and reached the superficial layers of the hippocampus. The early 
biochemical commitment of hippocampal Cck+ interneurons was confirmed by consistent co-
expression of DsRed/CR/CB1R by E14.5. By E18.5 Cck+/GAD67+/CR+ interneuron lamination 
largely resembled that reported for mature tissue, settling in upper layers II/III of the cortex 
and SR/SLM of the hippocampus. 
3.4.3 Electrophysiological characterization of migrating Cck-positive interneurons 
In order to evaluate functional development, patch-clamp electrophysiology was used to 
determine passive membrane properties, excitability and ion channel expression. For 
prenatal time points we recorded cells at the pallio-subpallial boundary of the CGE (E12.5), 
within the tangential migratory stream (E14.5) and in the hippocampus SR/SLM region 
(E18.5). For postnatal recordings (P16-P20) we recorded in SR of dorsal hippocampus. The 
excitability of Cck-positive CGE-derived cells was measured in current-clamp mode and 
compared across different prenatal ages. Developmental K+ current profiles were evaluated 
using voltage-clamp recordings to pharmacologically dissect TEA-sensitive K+-currents and 4-
AP-sensitive A-type K+-currents. In short, we observed the first signs of excitability in Cck+ 
interneurons by E14.5, with a resting membrane potential significantly more hyperpolarized 
compared to E12.5. 4-AP sensitive A-type K+ currents were detected by E14.5. In order to 
evaluate morphological changes during development, Cck+ interneurons were filled with 
Lucifer-yellow during recordings. We observed a shift from the expected bipolar migratory 
morphology at E12.5/E14.5 to an elongated soma with increased dendritic complexity by 
E18.5. Moreover, by E18.5 interneurons exhibited significantly more hyperpolarized resting 
membrane potentials, reduced input resistances and reliably fired action potentials in the 4-
12 Hz range. 4AP-sensitive A-type K+ currents increased by 1.5-fold at E18.5 comparted to 
E14.5, with a further increase in the adult, which in our hands, was the most reliable 
parameter that positively correlated with cell maturity.  
Thus, in study IV we used a combinatorial approach to selectively target and interrogate Cck+ 
interneurons throughout development from early prenatal stages. Interneuron subtype-
specific malfunction has been associated with numerous psychiatric diseases including 
schizophrenia, autism and intellectual disabilities [78]. A cell specific approach is necessary to 
investigate the physiology of specific interneuron cohorts in each of these disorders. 
Combining DsRedT3/Cck transgenic mice with immunohistochemistry, whole brain imaging 
and electrophysiology offers a powerful multiparametric approach for selectively 
characterizing Cck-expressing interneurons from early embryonic stages through 
development. The live reporting of Cck-expressing cells in DsRedT3/Cck transgenic mice 
further makes them available for cell migratory assays, calcium imaging, and two-photon 
imaging for future in vitro and in vivo experiments in both physiological and 
neuropathological models. 
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4 CONCLUSIONS 
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Endocannabinoids are key regulators of neurite outgrowth in the embryonic brain due to 
CB1R localization in the growth cone and a well-orchestrated compartmentalization of eCB 
machinery along the elongating neurite and across heterogeneous cells. Indeed, non-
physiological eCB levels during brain development are sufficient to induce long-lasting 
neuronal network impairments. Evidence provided in this work highlighted that: 
 
Study I: prenatal CB1R manipulation permanently reshapes septo-hippocampal cholinergic 
projections 
: NGF binds to TrkA in cholinergic neurites, inducing growth cone-localized MAGL 
degradation via BRCA1, thus cell-autonomously enhancing 2-AG signalling and 
neurite differentiation 
 
Study II: MAGL inhibition induces supra-physiological 2-AG levels, leading to axonal 
fasciculation and premature differentiation of oligodendrocytes within axonal 
bundles    
: supra-physiological 2-AG levels induce Slit2 overproduction in CB2R positive 
oligodendrocytes and Robo1 import into CB1R positive growth cones 
: supra-physiological 2-AG levels induce growth cone repulsion via Slit2/Robo1 
interactions 
 
Study III: prenatal exposure to THC permanently alters synaptic connectivity and 
physiological responses in the adult offspring 
:  prenatal THC exposure induces SCG10 degradation in the embryonic neocortex 
of mice and in the foetal human hippocampus 
:  prenatal THC binds to CB1Rs and recruits JNK1 to induce SCG10 proteasomal 
degradation, promoting aberrant growth cone development 
 
Study IV:  CGE-derived Cck-expressing interneurons emerge at the palliosubpallial boundary 
at E12.5, tangentially migrate to reach the hippocampus by E14.5 and exhibit 
significant anatomical complexity by E18.5 
: Cck positive interneurons express TEA-sensitive K+ currents as early as E12.5 and 
exhibit mature electrophysiological features such as hyperpolarized resting 
membrane potentials and sustained action potential firing by E18.5. A-type K+ 
currents are detected from E14.5 and further increase in a manner that correlates 
with the migratory phase and maturity of Cck interneurons. 
 
Axonal pathfinding, projection development, and synaptic targeting are compromised by eCB 
imbalances. Thus, exogenous inputs with potential to alter the delicate balance within the 
eCB system should be carefully monitored during pregnancy. Additionally, unveiling 
molecular determinants of critical events during brain development, is possibly the shortest 
path to understanding neurodevelopmental disorders such as schizophrenia, autism and 
intellectual disabilities.  
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